P5Yfalse--12-31Q320230000019584YesYesP5YP5YP3YP3YP3YP3Y00000195842021-11-3000000195842021-05-310000019584us-gaap:TreasuryStockCommonMember2023-09-300000019584us-gaap:RetainedEarningsMember2023-09-300000019584us-gaap:DeferredCompensationShareBasedPaymentsMember2023-09-300000019584us-gaap:CommonStockMember2023-09-300000019584us-gaap:AdditionalPaidInCapitalMember2023-09-300000019584us-gaap:TreasuryStockCommonMember2023-06-300000019584us-gaap:RetainedEarningsMember2023-06-300000019584us-gaap:DeferredCompensationShareBasedPaymentsMember2023-06-300000019584us-gaap:CommonStockMember2023-06-300000019584us-gaap:AdditionalPaidInCapitalMember2023-06-3000000195842023-06-300000019584us-gaap:TreasuryStockCommonMember2022-12-310000019584us-gaap:RetainedEarningsMember2022-12-310000019584us-gaap:DeferredCompensationShareBasedPaymentsMember2022-12-310000019584us-gaap:CommonStockMember2022-12-310000019584us-gaap:AdditionalPaidInCapitalMember2022-12-310000019584us-gaap:TreasuryStockCommonMember2022-09-300000019584us-gaap:RetainedEarningsMember2022-09-300000019584us-gaap:DeferredCompensationShareBasedPaymentsMember2022-09-300000019584us-gaap:CommonStockMember2022-09-300000019584us-gaap:AdditionalPaidInCapitalMember2022-09-300000019584us-gaap:TreasuryStockCommonMember2022-06-300000019584us-gaap:RetainedEarningsMember2022-06-300000019584us-gaap:DeferredCompensationShareBasedPaymentsMember2022-06-300000019584us-gaap:CommonStockMember2022-06-300000019584us-gaap:AdditionalPaidInCapitalMember2022-06-3000000195842022-06-300000019584us-gaap:TreasuryStockCommonMember2021-12-310000019584us-gaap:RetainedEarningsMember2021-12-310000019584us-gaap:DeferredCompensationShareBasedPaymentsMember2021-12-310000019584us-gaap:CommonStockMember2021-12-310000019584us-gaap:AdditionalPaidInCapitalMember2021-12-310000019584che:CompensationIncentiveCommitteeMemberche:PerformanceBasedTotalShareholderReturnTargetsMember2023-02-172023-02-170000019584che:CompensationIncentiveCommitteeMemberche:PerformanceBasedEarningsPerShareTargetsMember2023-02-172023-02-170000019584che:PerformanceBasedTotalShareholderReturnTargetsMember2023-01-012023-09-300000019584che:PerformanceBasedEarningsPerShareTargetsMember2023-01-012023-09-300000019584che:WaterRestorationMemberche:SegmentRotoRooterMember2023-07-012023-09-300000019584che:ShortTermCoreServiceJobsMemberche:SegmentRotoRooterMember2023-07-012023-09-300000019584che:RoutineHomeCareMemberche:MedicareMember2023-07-012023-09-300000019584che:RoutineHomeCareMemberche:MedicaidMember2023-07-012023-09-300000019584che:RoutineHomeCareMemberche:CommercialInsuranceMember2023-07-012023-09-300000019584che:PlumbingMemberche:SegmentRotoRooterMember2023-07-012023-09-300000019584che:OtherShortTermCoreServiceJobsMemberche:SegmentRotoRooterMember2023-07-012023-09-300000019584che:InpatientCareMemberche:MedicareMember2023-07-012023-09-300000019584che:InpatientCareMemberche:MedicaidMember2023-07-012023-09-300000019584che:InpatientCareMemberche:CommercialInsuranceMember2023-07-012023-09-300000019584che:FranchiseFeesMemberche:SegmentRotoRooterMember2023-07-012023-09-300000019584che:ExcavationMemberche:SegmentRotoRooterMember2023-07-012023-09-300000019584che:DrainCleaningMemberche:SegmentRotoRooterMember2023-07-012023-09-300000019584che:ContractorRevenueMemberche:SegmentRotoRooterMember2023-07-012023-09-300000019584che:ContinuousCareMemberche:MedicareMember2023-07-012023-09-300000019584che:ContinuousCareMemberche:MedicaidMember2023-07-012023-09-300000019584che:ContinuousCareMemberche:CommercialInsuranceMember2023-07-012023-09-300000019584che:CareServicesTotalMemberche:MedicareMember2023-07-012023-09-300000019584che:CareServicesTotalMemberche:MedicaidMember2023-07-012023-09-300000019584che:CareServicesTotalMemberche:CommercialInsuranceMember2023-07-012023-09-300000019584che:AllOtherMemberche:SegmentRotoRooterMember2023-07-012023-09-300000019584che:RoutineHomeCareMember2023-07-012023-09-300000019584che:InpatientCareMember2023-07-012023-09-300000019584che:ContinuousCareMember2023-07-012023-09-300000019584che:CareServicesTotalMember2023-07-012023-09-300000019584che:AllOtherRevenueSelfPayRespiteCareEct.Member2023-07-012023-09-300000019584che:RotoRooterMemberche:FranchiseFeesMemberche:AnnualizedMemberus-gaap:FranchiseRightsMember2023-01-012023-09-300000019584che:RotoRooterMemberche:FranchiseFeesMemberus-gaap:FranchiseRightsMember2023-01-012023-09-300000019584che:WaterRestorationMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584che:ShortTermCoreServiceJobsMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584che:RoutineHomeCareMemberche:MedicareMember2023-01-012023-09-300000019584che:RoutineHomeCareMemberche:MedicaidMember2023-01-012023-09-300000019584che:RoutineHomeCareMemberche:CommercialInsuranceMember2023-01-012023-09-300000019584che:PlumbingMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584che:OtherShortTermCoreServiceJobsMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584che:InpatientCareMemberche:MedicareMember2023-01-012023-09-300000019584che:InpatientCareMemberche:MedicaidMember2023-01-012023-09-300000019584che:InpatientCareMemberche:CommercialInsuranceMember2023-01-012023-09-300000019584che:FranchiseFeesMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584che:ExcavationMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584che:DrainCleaningMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584che:ContractorRevenueMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584che:ContinuousCareMemberche:MedicareMember2023-01-012023-09-300000019584che:ContinuousCareMemberche:MedicaidMember2023-01-012023-09-300000019584che:ContinuousCareMemberche:CommercialInsuranceMember2023-01-012023-09-300000019584che:CareServicesTotalMemberche:MedicareMember2023-01-012023-09-300000019584che:CareServicesTotalMemberche:MedicaidMember2023-01-012023-09-300000019584che:CareServicesTotalMemberche:CommercialInsuranceMember2023-01-012023-09-300000019584che:AllOtherMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584che:RoutineHomeCareMember2023-01-012023-09-300000019584che:InpatientCareMember2023-01-012023-09-300000019584che:ContinuousCareMember2023-01-012023-09-300000019584che:CareServicesTotalMember2023-01-012023-09-300000019584che:AllOtherRevenueSelfPayRespiteCareEct.Member2023-01-012023-09-300000019584che:WaterRestorationMemberche:SegmentRotoRooterMember2022-07-012022-09-300000019584che:ShortTermCoreServiceJobsMemberche:SegmentRotoRooterMember2022-07-012022-09-300000019584che:RoutineHomeCareMemberche:MedicareMember2022-07-012022-09-300000019584che:RoutineHomeCareMemberche:MedicaidMember2022-07-012022-09-300000019584che:RoutineHomeCareMemberche:CommercialInsuranceMember2022-07-012022-09-300000019584che:PlumbingMemberche:SegmentRotoRooterMember2022-07-012022-09-300000019584che:OtherShortTermCoreServiceJobsMemberche:SegmentRotoRooterMember2022-07-012022-09-300000019584che:InpatientCareMemberche:MedicareMember2022-07-012022-09-300000019584che:InpatientCareMemberche:MedicaidMember2022-07-012022-09-300000019584che:InpatientCareMemberche:CommercialInsuranceMember2022-07-012022-09-300000019584che:FranchiseFeesMemberche:SegmentRotoRooterMember2022-07-012022-09-300000019584che:ExcavationMemberche:SegmentRotoRooterMember2022-07-012022-09-300000019584che:DrainCleaningMemberche:SegmentRotoRooterMember2022-07-012022-09-300000019584che:ContractorRevenueMemberche:SegmentRotoRooterMember2022-07-012022-09-300000019584che:ContinuousCareMemberche:MedicareMember2022-07-012022-09-300000019584che:ContinuousCareMemberche:MedicaidMember2022-07-012022-09-300000019584che:ContinuousCareMemberche:CommercialInsuranceMember2022-07-012022-09-300000019584che:CareServicesTotalMemberche:MedicareMember2022-07-012022-09-300000019584che:CareServicesTotalMemberche:MedicaidMember2022-07-012022-09-300000019584che:CareServicesTotalMemberche:CommercialInsuranceMember2022-07-012022-09-300000019584che:AllOtherMemberche:SegmentRotoRooterMember2022-07-012022-09-300000019584che:RoutineHomeCareMember2022-07-012022-09-300000019584che:InpatientCareMember2022-07-012022-09-300000019584che:ContinuousCareMember2022-07-012022-09-300000019584che:CareServicesTotalMember2022-07-012022-09-300000019584che:AllOtherRevenueSelfPayRespiteCareEct.Member2022-07-012022-09-300000019584che:WaterRestorationMemberche:SegmentRotoRooterMember2022-01-012022-09-300000019584che:ShortTermCoreServiceJobsMemberche:SegmentRotoRooterMember2022-01-012022-09-300000019584che:RoutineHomeCareMemberche:MedicareMember2022-01-012022-09-300000019584che:RoutineHomeCareMemberche:MedicaidMember2022-01-012022-09-300000019584che:RoutineHomeCareMemberche:CommercialInsuranceMember2022-01-012022-09-300000019584che:PlumbingMemberche:SegmentRotoRooterMember2022-01-012022-09-300000019584che:OtherShortTermCoreServiceJobsMemberche:SegmentRotoRooterMember2022-01-012022-09-300000019584che:InpatientCareMemberche:MedicareMember2022-01-012022-09-300000019584che:InpatientCareMemberche:MedicaidMember2022-01-012022-09-300000019584che:InpatientCareMemberche:CommercialInsuranceMember2022-01-012022-09-300000019584che:FranchiseFeesMemberche:SegmentRotoRooterMember2022-01-012022-09-300000019584che:ExcavationMemberche:SegmentRotoRooterMember2022-01-012022-09-300000019584che:DrainCleaningMemberche:SegmentRotoRooterMember2022-01-012022-09-300000019584che:ContractorRevenueMemberche:SegmentRotoRooterMember2022-01-012022-09-300000019584che:ContinuousCareMemberche:MedicareMember2022-01-012022-09-300000019584che:ContinuousCareMemberche:MedicaidMember2022-01-012022-09-300000019584che:ContinuousCareMemberche:CommercialInsuranceMember2022-01-012022-09-300000019584che:CareServicesTotalMemberche:MedicareMember2022-01-012022-09-300000019584che:CareServicesTotalMemberche:MedicaidMember2022-01-012022-09-300000019584che:CareServicesTotalMemberche:CommercialInsuranceMember2022-01-012022-09-300000019584che:AllOtherMemberche:SegmentRotoRooterMember2022-01-012022-09-300000019584che:RoutineHomeCareMember2022-01-012022-09-300000019584che:InpatientCareMember2022-01-012022-09-300000019584che:ContinuousCareMember2022-01-012022-09-300000019584che:CareServicesTotalMember2022-01-012022-09-300000019584che:AllOtherRevenueSelfPayRespiteCareEct.Member2022-01-012022-09-300000019584che:TwoThousandTwentyTwoCreditAgreementMemberus-gaap:MediumTermNotesMember2023-04-282023-04-280000019584che:TwoThousandTwentyTwoCreditAgreementMemberus-gaap:MediumTermNotesMember2023-01-012023-03-310000019584che:FranchiseGeorgiaMemberche:SegmentRotoRooterMember2023-09-262023-09-260000019584che:FranchiseSouthCarolinaMemberche:SegmentRotoRooterMember2023-06-012023-06-010000019584che:FranchisesNewJerseyMemberche:SegmentRotoRooterMember2022-01-012022-12-310000019584che:SegmentRotoRooterMember2019-01-012019-12-310000019584us-gaap:OperatingSegmentsMemberche:SegmentVitasMember2023-07-012023-09-300000019584us-gaap:OperatingSegmentsMemberche:SegmentRotoRooterMember2023-07-012023-09-300000019584us-gaap:OperatingSegmentsMember2023-07-012023-09-300000019584us-gaap:CorporateMember2023-07-012023-09-300000019584us-gaap:OperatingSegmentsMemberche:SegmentVitasMember2023-01-012023-09-300000019584us-gaap:OperatingSegmentsMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584us-gaap:OperatingSegmentsMember2023-01-012023-09-300000019584us-gaap:CorporateMember2023-01-012023-09-300000019584us-gaap:OperatingSegmentsMemberche:SegmentVitasMember2022-07-012022-09-300000019584us-gaap:OperatingSegmentsMemberche:SegmentRotoRooterMember2022-07-012022-09-300000019584us-gaap:OperatingSegmentsMember2022-07-012022-09-300000019584us-gaap:CorporateMember2022-07-012022-09-300000019584us-gaap:OperatingSegmentsMemberche:SegmentVitasMember2022-01-012022-09-300000019584us-gaap:OperatingSegmentsMemberche:SegmentRotoRooterMember2022-01-012022-09-300000019584us-gaap:OperatingSegmentsMember2022-01-012022-09-300000019584us-gaap:CorporateMember2022-01-012022-09-300000019584che:AuditOfProvisionOfElevatedLevelOfCareHospiceServicesMember2022-08-290000019584che:AuditOfProvisionOfElevatedLevelOfCareHospiceServicesMember2023-01-012023-09-300000019584che:AuditOfProvisionOfElevatedLevelOfCareHospiceServicesMember2022-08-292022-08-290000019584che:TwoThousandTwentyTwoCreditAgreementMember2023-03-310000019584che:TwoThousandTwentyTwoCreditAgreementMember2022-12-310000019584che:TwoThousandTwentyTwoCreditAgreementMemberche:ExpansionFeatureMember2022-06-280000019584che:TwoThousandTwentyTwoCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-09-300000019584che:TwoThousandTwentyTwoCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-06-280000019584che:TwoThousandTwentyTwoCreditAgreementMemberus-gaap:MediumTermNotesMember2022-06-280000019584che:TwoThousandTwentyTwoCreditAgreementMember2023-09-300000019584srt:MinimumMember2023-09-300000019584srt:MaximumMember2023-09-300000019584us-gaap:FairValueInputsLevel1Member2023-09-300000019584us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300000019584us-gaap:FairValueInputsLevel1Member2022-12-310000019584che:RotoRooterMember2023-01-012023-09-300000019584che:SegmentVitasMember2023-09-300000019584che:RotoRooterMember2023-09-300000019584che:SegmentVitasMember2022-12-310000019584che:RotoRooterMember2022-12-310000019584che:PerformanceBasedTotalShareholderReturnTargetsMember2023-02-170000019584che:PerformanceBasedEarningsPerShareTargetsMember2023-02-170000019584us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000019584us-gaap:RetainedEarningsMember2023-07-012023-09-300000019584us-gaap:DeferredCompensationShareBasedPaymentsMember2023-07-012023-09-300000019584us-gaap:CommonStockMember2023-07-012023-09-300000019584us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000019584us-gaap:TreasuryStockCommonMember2023-01-012023-09-300000019584us-gaap:RetainedEarningsMember2023-01-012023-09-300000019584us-gaap:DeferredCompensationShareBasedPaymentsMember2023-01-012023-09-300000019584us-gaap:CommonStockMember2023-01-012023-09-300000019584us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000019584us-gaap:TreasuryStockCommonMember2022-07-012022-09-300000019584us-gaap:RetainedEarningsMember2022-07-012022-09-300000019584us-gaap:DeferredCompensationShareBasedPaymentsMember2022-07-012022-09-300000019584us-gaap:CommonStockMember2022-07-012022-09-300000019584us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000019584us-gaap:TreasuryStockCommonMember2022-01-012022-09-300000019584us-gaap:RetainedEarningsMember2022-01-012022-09-300000019584us-gaap:DeferredCompensationShareBasedPaymentsMember2022-01-012022-09-300000019584us-gaap:CommonStockMember2022-01-012022-09-300000019584us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000019584che:TwoThousandTwentyTwoCreditAgreementMemberus-gaap:MediumTermNotesMember2023-09-300000019584che:TwoThousandTwentyTwoCreditAgreementMemberus-gaap:MediumTermNotesMember2023-01-012023-09-300000019584us-gaap:FairValueInputsLevel2Member2022-12-310000019584us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310000019584us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-01-012023-09-300000019584che:MedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2023-01-012023-09-300000019584che:MedicareAndMedicaidMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2023-01-012023-09-300000019584che:MedicaidMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2023-01-012023-09-300000019584che:MedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2022-01-012022-12-310000019584che:MedicaidMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2022-01-012022-12-3100000195842022-09-3000000195842021-12-310000019584che:VitasMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-09-300000019584che:VitasMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-07-012023-09-300000019584che:VitasMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-01-012023-09-300000019584che:VitasMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-07-012022-09-300000019584che:VitasMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-01-012022-09-300000019584che:RotoRooterMemberus-gaap:FranchiseRightsMember2019-12-310000019584che:RotoRooterMember2019-01-012019-12-310000019584che:RotoRooterMemberche:AnnualizedThrough2026Memberus-gaap:FranchiseRightsMember2023-01-012023-09-300000019584che:RotoRooterMemberus-gaap:FranchiseRightsMember2023-01-012023-09-300000019584che:RoomAndBoardMember2023-07-012023-09-300000019584che:RoomAndBoardMember2023-01-012023-09-300000019584che:RoomAndBoardMember2022-07-012022-09-300000019584che:RoomAndBoardMember2022-01-012022-09-300000019584che:AuditOfProvisionOfElevatedLevelOfCareHospiceServicesMember2022-07-140000019584che:VitasMember2022-08-292022-08-290000019584che:AdoptionOfAsc606Memberche:SegmentVitasMember2023-01-012023-09-300000019584che:FloridaProviderMemberche:SegmentVitasMember2022-01-012022-12-310000019584che:VitasMember2020-10-162020-10-160000019584che:SegmentVitasMember2023-01-012023-09-3000000195842022-07-012022-09-300000019584srt:MaximumMemberche:SegmentVitasMember2023-01-012023-09-300000019584che:MedicareCapServiceMember2023-07-012023-09-300000019584che:MedicareCapServiceMember2023-01-012023-09-300000019584che:MedicareCapServiceMember2022-07-012022-09-300000019584che:MedicareCapServiceMember2022-01-012022-09-3000000195842022-01-012022-09-3000000195842023-07-012023-09-300000019584che:SegmentRotoRooterMember2023-07-012023-09-300000019584che:SegmentRotoRooterMember2022-07-012022-09-300000019584che:SegmentRotoRooterMember2022-01-012022-09-300000019584che:ImplicitPriceConcessionsMember2023-07-012023-09-300000019584che:ImplicitPriceConcessionsMember2023-01-012023-09-300000019584che:ImplicitPriceConcessionsMember2022-07-012022-09-300000019584che:ImplicitPriceConcessionsMember2022-01-012022-09-300000019584srt:MinimumMember2023-01-012023-09-300000019584srt:MaximumMember2023-01-012023-09-300000019584srt:MinimumMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584srt:MaximumMemberche:SegmentRotoRooterMember2023-01-012023-09-300000019584che:SegmentRotoRooterMember2023-01-012023-09-3000000195842023-09-3000000195842022-12-3100000195842023-01-012023-09-300000019584che:AuditOfProvisionOfElevatedLevelOfCareHospiceServicesMember2022-07-142022-07-140000019584che:VitasMember2017-10-302017-10-30iso4217:USDxbrli:sharesxbrli:sharesche:itemxbrli:pureiso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x    Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended September 30, 2023

o    Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number: 1-8351

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

31-0791746

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

255 E. Fifth Street, Suite 2600, Cincinnati, Ohio

45202

(Address of principal executive offices)

(Zip code)

(513) 762-6690

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  

x

No  

o  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes  

x

No  

o  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Large Accelerated Filer

x

Accelerated Filer

o

Non-accelerated Filer

o

Smaller Reporting Company

o

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  

 o 

No  

x  

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange

on which Registered

Amount

Date

Capital Stock $1 Par Value

CHE

New York Stock Exchange

15,062,308 Shares

September 30, 2023

 


-1-


CHEMED CORPORATION AND

SUBSIDIARY COMPANIES

Index

Page No.

PART I. FINANCIAL INFORMATION:

Item 1. Financial Statements

Unaudited Consolidated Balance Sheets -

September 30, 2023 and December 31, 2022

3

Unaudited Consolidated Statements of Income -

Three and nine months ended September 30, 2023 and 2022

4

Unaudited Consolidated Statements of Cash Flows -

Nine months ended September 30, 2023 and 2022

5

Unaudited Consolidated Statements of Changes in Stockholders’ Equity-

Three and nine months ended September 30, 2023 and 2022

6

Notes to Unaudited Consolidated Financial Statements

8

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

22

Item 3. Quantitative and Qualitative Disclosures about Market Risk

39

Item 4. Controls and Procedures

39

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

39

Item 1A. Risk Factors

39

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

40

Item 3. Defaults Upon Senior Securities

40

Item 4. Mine Safety Disclosures

40

Item 5. Other Information

40

Item 6. Exhibits

41

EX – 31.1

EX – 31.2

EX – 31.3

EX – 32.1

EX – 32.2

EX – 32.3

EX – 101

EX – 104

SIGNATURES

42


-2-


 

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

UNAUDITED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

September 30, 2023

December 31, 2022

ASSETS

Current assets

Cash and cash equivalents

$

173,150 

$

74,126 

Accounts receivable less allowances

168,031 

139,408 

Inventories

12,511 

10,272 

Prepaid income taxes

11,337 

18,515 

Prepaid expenses

29,510 

30,291 

Total current assets

394,539 

272,612 

Investments of deferred compensation plans held in trust

104,410 

93,196 

Properties and equipment, at cost, less accumulated depreciation of $347,909 (2022- $335,920)

205,462 

199,714 

Lease right of use asset

123,353 

135,662 

Identifiable intangible assets less accumulated amortization of $46,449 (2022 - $67,716)

92,768 

99,726 

Goodwill

584,977 

581,295 

Other assets

56,570 

59,807 

Total Assets

$

1,562,079 

$

1,442,012 

LIABILITIES

Current liabilities

Accounts payable

$

56,508 

$

41,884 

Current portion of long-term debt

-

5,000 

Income taxes

5,135 

-

Accrued insurance

61,122 

58,515 

Accrued compensation

74,865 

87,350 

Accrued legal

6,626 

4,456 

Short-term lease liability

37,615 

38,996 

Other current liabilities

55,348 

61,004 

Total current liabilities

297,219 

297,205 

Deferred income taxes

30,381 

38,613 

Long-term debt

-

92,500 

Deferred compensation liabilities

102,815 

92,330 

Long-term lease liability

99,346 

110,513 

Other liabilities

13,075 

12,136 

Total Liabilities

542,836 

643,297 

Commitments and contingencies (Note 10)

 

 

STOCKHOLDERS' EQUITY

Capital stock - authorized 80,000,000 shares $1 par; issued 37,013,253 shares (2022 - 36,795,792 shares)

37,013 

36,796 

Paid-in capital

1,254,356 

1,149,899 

Retained earnings

2,362,928 

2,197,918 

Treasury stock - 22,005,711 shares (2022 - 21,920,993 shares)

(2,637,102)

(2,588,145)

Deferred compensation payable in Company stock

2,048 

2,247 

Total Stockholders' Equity

1,019,243 

798,715 

Total Liabilities and Stockholders' Equity

$

1,562,079 

$

1,442,012 

See Accompanying Notes to Unaudited Consolidated Financial Statements.

 


-3-


 

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

UNAUDITED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

Three Months Ended September 30,

Nine Months Ended September 30,

2023

2022

2023

2022

Service revenues and sales

$

564,532 

$

526,472 

$

1,678,505 

$

1,588,309 

Cost of services provided and goods sold (excluding depreciation)

362,358 

346,934 

1,107,256 

1,020,307 

Selling, general and administrative expenses

99,602 

83,992 

294,684 

261,799 

Depreciation

12,858 

12,154 

37,778 

37,006 

Amortization

2,521 

2,520 

7,548 

7,558 

Other operating expense/(income)

343 

15 

2,064 

(530)

Total costs and expenses

477,682 

445,615 

1,449,330 

1,326,140 

Income from operations

86,850 

80,857 

229,175 

262,169 

Interest expense

(444)

(1,271)

(2,766)

(2,983)

Other income/(expense) - net

6,859 

(3,115)

8,365 

(11,907)

Income before income taxes

93,265 

76,471 

234,774 

247,279 

Income taxes

(18,307)

(19,598)

(52,318)

(59,781)

Net income

$

74,958 

$

56,873 

$

182,456 

$

187,498 

Earnings Per Share:

Net income

$

4.97 

$

3.82 

$

12.14 

$

12.55 

Average number of shares outstanding

15,075 

14,888 

15,034 

14,935 

Diluted Earnings Per Share:

Net income

$

4.93 

$

3.78 

$

12.02 

$

12.41 

Average number of shares outstanding

15,200 

15,042 

15,178 

15,114 

Cash Dividends Per Share

$

0.40 

$

0.38 

$

1.16 

$

1.10 

See Accompanying Notes to Unaudited Consolidated Financial Statements.

 


-4-


 

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Nine Months Ended September 30,

2023

2022

Cash Flows from Operating Activities

Net income

$

182,456 

$

187,498 

Adjustments to reconcile net income to net cash provided

by operating activities:

Depreciation and amortization

45,326 

44,564 

Stock option expense

22,376 

19,343 

(Benefit)/provision for deferred income taxes

(8,232)

10,408 

Noncash long-term incentive compensation

6,637 

4,343 

Litigation settlements

2,050 

-

Noncash directors' compensation

1,444 

1,170 

Amortization of debt issuance costs

500 

247 

Changes in operating assets and liabilities:

(Increase)/decrease in accounts receivable

(27,843)

16,166 

Increase in inventories

(2,239)

(360)

Decrease in prepaid expenses

781 

1,257 

Decrease in accounts payable and other current liabilities

(15,815)

(15,765)

Change in current income taxes

12,314 

(10,277)

Net change in lease assets and liabilities

(892)

313 

Increase in other assets

(8,622)

(42,424)

Increase/(decrease) in other liabilities

11,426 

(6,555)

Other sources/(uses)

69 

(241)

Net cash provided by operating activities

221,736 

209,687 

Cash Flows from Investing Activities

Capital expenditures

(45,075)

(39,066)

Proceeds from sale of fixed assets

506 

2,037 

Business combinations, net of cash acquired

(3,994)

(2,044)

Other uses

(409)

(841)

Net cash used by investing activities

(48,972)

(39,914)

Cash Flows from Financing Activities

Payments on other long-term debt

(97,500)

(1,250)

Proceeds from other long-term debt

-

100,000 

Proceeds from exercise of stock options

58,277 

17,128 

Purchases of treasury stock

(27,769)

(101,539)

Dividends paid

(17,446)

(16,391)

Change in cash overdrafts payable

16,182 

5,535 

Capital stock surrendered to pay taxes on stock-based compensation

(5,446)

(12,497)

Debt issuance costs

-

(1,584)

Payments on revolving line of credit

-

(299,400)

Proceeds from revolving line of credit

-

116,500 

Other sources/(uses)

(38)

(1,389)

Net cash used by financing activities

(73,740)

(194,887)

Increase/(Decrease) in Cash and Cash Equivalents

99,024 

(25,114)

Cash and cash equivalents at beginning of period

74,126 

32,895 

Cash and cash equivalents at end of period

$

173,150 

$

7,781 

See Accompanying Notes to Unaudited Consolidated Financial Statements.

 


-5-


 

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except per share data)

For the three months ended September 30, 2023 and 2022:

Deferred

Compensation

Treasury

Payable in

Capital

Paid-in

Retained

Stock-

Company

Stock

Capital

Earnings

at Cost

Stock

Total

Balance at June 30, 2023

$

36,996 

$

1,240,415 

$

2,294,004 

$

(2,621,657)

$

2,321 

$

952,079 

Net income

-

-

74,958 

-

-

74,958 

Dividends paid ($0.40 per share)

-

-

(6,034)

-

-

(6,034)

Stock awards and exercise of stock options

17 

14,462 

-

(1,372)

-

13,107 

Purchases of treasury stock

-

-

-

(14,344)

-

(14,344)

Other

-

(521)

-

271 

(273)

(523)

Balance at September 30, 2023

$

37,013 

$

1,254,356 

$

2,362,928 

$

(2,637,102)

$

2,048 

$

1,019,243 

Deferred

Compensation

Treasury

Payable in

Capital

Paid-in

Retained

Stock-

Company

Stock

Capital

Earnings

at Cost

Stock

Total

Balance at June 30, 2022

$

36,651 

$

1,089,129 

$

2,090,214 

$

(2,533,306)

$

2,272 

$

684,960 

Net income

-

-

56,873 

-

-

56,873 

Dividends paid ($0.38 per share)

-

-

(5,669)

-

-

(5,669)

Stock awards and exercise of stock options

19 

12,295 

-

(1,916)

-

10,398 

Purchases of treasury stock

-

-

-

(23,884)

-

(23,884)

Other

-

(1,263)

-

(35)

36 

(1,262)

Balance at September 30, 2022

$

36,670 

$

1,100,161 

$

2,141,418 

$

(2,559,141)

$

2,308 

$

721,416 

See Accompanying Notes to Unaudited Consolidated Financial Statements.


-6-


CHEMED CORPORATION AND SUBSIDIARY COMPANIES

UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except per share data)

For the nine months ended September 30, 2023 and 2022:

Deferred

Compensation

Treasury

Payable in

Capital

Paid-in

Retained

Stock-

Company

Stock

Capital

Earnings

at Cost

Stock

Total

Balance at December 31, 2022

$

36,796 

$

1,149,899 

$

2,197,918 

$

(2,588,145)

$

2,247 

$

798,715 

Net income

-

-

182,456 

-

-

182,456 

Dividends paid ($1.16 per share)

-

-

(17,446)

-

-

(17,446)

Stock awards and exercise of stock options

217 

104,457 

-

(21,386)

-

83,288 

Purchases of treasury stock

-

-

-

(27,769)

-

(27,769)

Other

-

-

-

198 

(199)

(1)

Balance at September 30, 2023

$

37,013 

$

1,254,356 

$

2,362,928 

$

(2,637,102)

$

2,048 

$

1,019,243 

Deferred

Compensation

Treasury

Payable in

Capital

Paid-in

Retained

Stock-

Company

Stock

Capital

Earnings

at Cost

Stock

Total

Balance at December 31, 2021

$

36,514 

$

1,044,341 

$

1,970,311 

$

(2,430,094)

$

2,201 

$

623,273 

Net income

-

-

187,498 

-

-

187,498 

Dividends paid ($1.10 per share)

-

-

(16,391)

-

-

(16,391)

Stock awards and exercise of stock options

156 

57,172 

-

(27,842)

-

29,486 

Purchases of treasury stock

-

-

-

(101,098)

-

(101,098)

Other

-

(1,352)

-

(107)

107 

(1,352)

Balance at September 30, 2022

$

36,670 

$

1,100,161 

$

2,141,418 

$

(2,559,141)

$

2,308 

$

721,416 

See Accompanying Notes to Unaudited Consolidated Financial Statements.


-7-


CHEMED CORPORATION AND SUBSIDIARY COMPANIES

Notes to Unaudited Consolidated Financial Statements

1.    Basis of Presentation

As used herein, the terms “We,” “Company” and “Chemed” refer to Chemed Corporation or Chemed Corporation and its consolidated subsidiaries.

We have prepared the accompanying unaudited consolidated financial statements of Chemed in accordance with Rule 10-01 of SEC Regulation S-X. Consequently, we have omitted certain disclosures required under generally accepted accounting principles in the United States (“GAAP”) for complete financial statements. The December 31, 2022 balance sheet data were derived from audited financial statements but do not include all disclosures required by GAAP. However, in our opinion, the financial statements presented herein contain all adjustments, consisting only of normal recurring adjustments, necessary to state fairly our financial position, results of operations and cash flows. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 or any other future period, and we make no representations related thereto. These financial statements are prepared on the same basis as and should be read in conjunction with the audited Consolidated Financial Statements and related Notes included in our Annual Report on Form 10-K for the year ended December 31, 2022.

CLOUD COMPUTING

As of September 30, 2023, Roto-Rooter has no significant capitalized implementation costs related to cloud computing.

VITAS utilizes a human resources system that is considered a cloud computing arrangement. We have capitalized approximately $5.6 million related to implementation of this project which is included in prepaid assets in the accompanying balance sheets. The VITAS human resource system was placed into service in January 2020 and is being amortized over 5.7 years. For the three months ended September 30, 2023 and 2022, $249,000 has been amortized, respectively. For the nine months ended September 30, 2023 and 2022, $746,000 has been amortized, respectively.

INCOME TAXES

Our effective income tax rate was 19.6% in the third quarter of 2023 compared to 25.6% during the third quarter of 2022. Excess tax benefit on stock options exercised reduced our income tax expenses by $225,000 and $450,000 for the quarters ended September 30, 2023 and 2022, respectively.

Our effective income tax rate was 22.3% in the first nine months of 2023 compared to 24.2% during the first nine months of 2022. Excess tax benefit on stock options exercised reduced our income tax expenses by $3.4 million and $4.4 million for the first nine months ended September 30, 2023 and 2022, respectively.

During the third quarter of 2023, the Company recognized a tax benefit from realignment of its state and local corporate tax structure based on the location of operating resources and profitability by business segment. This benefit includes a reduction in current state and local tax expense and a one time benefit of $4.2 million in reduction of deferred tax liabilities reflecting the lower tax rates.

NON-CASH TRANSACTIONS

Included in the accompanying Consolidated Balance Sheets are $744,000 and $1.9 million of capitalized property and equipment which were not paid for as of September 30, 2023 and December 31, 2022, respectively. Accrued property and equipment purchases have been excluded from capital expenditures in the accompanying Consolidated Statements of Cash Flow. There are no material non-cash amounts included in interest expense for any period presented.

BUSINESS COMBINATIONS

We account for acquired businesses using the acquisition method of accounting. All assets acquired and liabilities assumed are recorded at their respective fair values at the date of acquisition. The determination of fair value involves estimates and the use of valuation techniques when market value is not readily available. We use various techniques to determine fair value in accordance with accepted valuation models, primarily the income approach. The significant assumptions used in developing fair values include, but are not limited to, revenue growth rates, the amount and timing of future cash flows, discount rates, useful lives, royalty rates and future tax rates. The excess of purchase price over the fair value of assets and liabilities acquired is recorded as goodwill. See Note 17 for discussion of recent acquisitions.

-8-


Quarterly amortization of intangible assets is mainly driven by two Roto-Rooter franchise acquisitions completed in 2019. The total purchase price of these acquisitions was $138.0 million. As part of the purchase price allocation, approximately $59.2 million was determined to be the value of reacquired franchise rights which are being amortized over the remaining life of each franchise agreement. The average remaining life on the reacquired franchise agreements was approximately seven years. Quarterly amortization of reacquired franchise rights for these two acquisitions is approximately $2.0 million ($8.1 million annualized through 2026). This contrasts to quarterly franchise fees historically collected from these two franchisees of approximately $470,000 ($1.9 million annualized).

ESTIMATES

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying Notes. Actual results could differ from those estimates. Disclosures of after-tax expenses and adjustments are based on estimates of the effective income tax rates for the applicable segments.

2.    Revenue Recognition

In May 2014, the FASB issued Accounting Standards Update “ASU No. 2014-09 – Revenue from Contracts with Customers.” The standard and subsequent amendments are intended to develop a common revenue standard for removing inconsistencies and weaknesses, improve comparability, provide for more useful information to users through improved disclosure requirements and simplify the preparation of financial statements. The standard is also referred to as Accounting Standards Codification No. 606 (“ASC 606”).

VITAS

Service revenue for VITAS is reported at the amount that reflects the ultimate consideration we expect to receive in exchange for providing patient care. These amounts are due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), and include variable consideration for revenue adjustments due to settlements of audits and reviews, as well as certain hospice-specific revenue capitations. Amounts are generally billed monthly or subsequent to patient discharge. Subsequent changes in the transaction price initially recognized are not significant.

Hospice services are provided on a daily basis and the type of service provided is determined based on a physician’s determination of each patient’s specific needs on that given day. Reimbursement rates for hospice services are on a per diem basis regardless of the type of service provided or the payor. Reimbursement rates from government programs are established by the appropriate governmental agency and are standard across all hospice providers. Reimbursement rates from health insurers are negotiated with each payor and generally structured to closely mirror the Medicare reimbursement model. The types of hospice services provided and associated reimbursement model for each are as follows:

Routine Home Care occurs when a patient receives hospice care in their home, including a nursing home setting.  The routine home care rate is paid for each day that a patient is in a hospice program and is not receiving one of the other categories of hospice care.  For Medicare patients, the routine home care rate reflects a two-tiered rate, with a higher rate for the first 60 days of a hospice patient’s care and a lower rate for days 61 and after.  In addition, there is a Service Intensity Add-on payment which covers direct home care visits conducted by a registered nurse or social worker in the last seven days of a hospice patient’s life, reimbursed up to 4 hours per day in 15 minute increments at the continuous home care rate.

General Inpatient Care occurs when a patient requires services in a controlled setting for a short period of time for pain control or symptom management which cannot be managed in other settings.  General inpatient care services must be provided in a Medicare or Medicaid certified hospital or long-term care facility or at a freestanding inpatient hospice facility with the required registered nurse staffing.

Continuous Home Care is provided to patients while at home, including a nursing home setting, during periods of crisis when intensive monitoring and care, primarily nursing care, is required in order to achieve palliation or management of acute medical symptoms.  Continuous home care requires a minimum of 8 hours of care within a 24-hour day, which begins at midnight.  The care must be predominantly nursing care provided by either a registered nurse or licensed nurse practitioner.  While the published Medicare continuous home care rates are daily rates, Medicare pays for continuous home care in 15 minute increments.  This 15 minute rate is calculated by dividing the daily rate by 96.

Respite Care permits a hospice patient to receive services on an inpatient basis for a short period of time in order to provide relief for the patient’s family or other caregivers from the demands of caring for the patient.  A hospice can receive payment for respite care for a given patient for up to five consecutive days at a time, after which respite care is reimbursed at the routine home care rate.

-9-


Each level of care represents a separate promise under the contract of care and is provided independently for each patient contingent upon the patient’s specific medical needs as determined by a physician. However, the clinical criteria used to determine a patient’s level of care is consistent across all patients, given that, each patient is subject to the same payor rules and regulations. As a result, we have concluded that each level of care is capable of being distinct and is distinct in the context of the contract. Furthermore, we have determined that each level of care represents a stand ready service provided as a series of either days or hours of patient care. We believe that the performance obligations for each level of care meet criteria to be satisfied over time. VITAS recognizes revenue based on the service output. VITAS believes this to be the most faithful depiction of the transfer of control of services as the patient simultaneously receives and consumes the benefits provided by our performance. Revenue is recognized on a daily or hourly basis for each patient in accordance with the reimbursement model for each type of service. VITAS’ performance obligations relate to contracts with an expected duration of less than one year. Therefore, VITAS has elected to apply the optional exception provided in ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially satisfied performance obligations referred to above relate to bereavement services provided to patients’ families for at least 12 months after discharge.

Care is provided to patients regardless of their ability to pay. Patients who meet our criteria for charity care are provided care without charge. There is no revenue or associated accounts receivable in the accompanying Consolidated Financial Statements related to charity care. The cost of providing charity care for the quarter ended September 30, 2023 and 2022 was $2.0 million and $1.9 million, respectively. The cost of providing charity care during the first nine months ended September 30, 2023 and 2022 was $6.1 million and $5.9 million, respectively. The cost of charity care is included in cost of services provided and goods sold and is calculated by taking the ratio of charity care days to total days of care and multiplying by the total cost of care.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance which vary in amount. VITAS also provides service to patients without a reimbursement source and may offer those patients discounts from standard charges. VITAS estimates the transaction price for patients with deductibles and coinsurance, along with those uninsured patients, based on historical experience and current conditions. The estimate of any contractual adjustments, discounts or implicit price concessions reduces the amount of revenue initially recognized. Subsequent changes to the estimate of the transaction price are recorded as adjustments to patient service revenue in the period of change. Subsequent changes that are determined to be the result of an adverse change in the patients’ ability to pay (i.e. change in credit risk) are recorded as bad debt expense. VITAS has no material adjustments related to subsequent changes in the estimate of the transaction price or subsequent changes as the result of an adverse change in the patient’s ability to pay for any period reported.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation and change over time. Medicare and Medicaid programs have broad authority to audit and review compliance with such laws and regulations and impose payment suspensions or modifications when merited. Additionally, the contracts we have with commercial health insurance payors provide for retroactive audit and review of claims. Settlement with third party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. The variable consideration is estimated based on the terms of the payment agreement, existing correspondence from the payor and our historical settlement activity. These estimates are adjusted in future periods, as new information becomes available.

We are subject to certain limitations on Medicare payments for services which are considered variable consideration, as follows:

Inpatient Cap. If the number of inpatient care days any hospice program provides to Medicare beneficiaries exceeds 20% of the total days of hospice care such program provided to all Medicare patients for an annual period beginning September 28, the days in excess of the 20% figure may be reimbursed only at the routine homecare rate. None of VITAS’ hospice programs exceeded the payment limits on inpatient services during the three months ended September 30, 2023 and 2022.

Medicare Cap. We are also subject to a Medicare annual per-beneficiary cap (“Medicare cap”). Compliance with the Medicare cap is measured in one of two ways based on a provider election. The “streamlined” method compares total Medicare payments received under a Medicare provider number with respect to services provided to all Medicare hospice care beneficiaries in the program or programs covered by that Medicare provider number with the product of the per-beneficiary cap amount and the number of Medicare beneficiaries electing hospice care for the first time from that hospice program or programs from September 28 through September 27 of the following year. At September 30, 2023, all our programs except one are using the “streamlined” method.

The “proportional” method compares the total Medicare payments received under a Medicare provider number with respect to services provided to all Medicare hospice care beneficiaries in the program or programs covered by the Medicare provider number between September 28 and September 27 of the following year with the product of the per beneficiary cap amount and a pro-rated number of Medicare beneficiaries receiving hospice services from that program during the same period. The pro-rated number of Medicare beneficiaries is calculated based on the ratio of

-10-


days the beneficiary received hospice services during the measurement period to the total number of days the beneficiary received hospice services.

We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether revenues are likely to exceed the annual per-beneficiary Medicare cap. Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective actions, which include changes to the patient mix and increased patient admissions. However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate revenue recognized during the government fiscal year that will require repayment to the Federal government under the Medicare cap and record an adjustment to revenue of an amount equal to a ratable portion of our best estimate for the year.

For VITAS’ patients in the nursing home setting in which Medicaid pays the nursing home room and board, VITAS serves as a pass-through between Medicaid and the nursing home. We are responsible for paying the nursing home for that patient’s room and board. Medicaid reimburses us for 95% of the amount we have paid. This results in a 5% net expense for VITAS related to nursing home room and board. This transaction creates a performance obligation in that VITAS is facilitating room and board being delivered to our patient. As a result, the 5% net expense is recognized as a contra-revenue account under ASC 606 in the accompanying financial statements.

The composition of patient care service revenue by payor and level of care for the quarter ended September 30, 2023 is as follows (in thousands):

Medicare

Medicaid

Commercial

Total

Routine home care

$

269,954 

$

11,187 

$

6,248 

$

287,389 

Continuous care

20,160 

870 

1,002 

22,032 

Inpatient care

23,983 

2,197 

1,638 

27,818 

$

314,097 

$

14,254 

$

8,888 

$

337,239 

All other revenue - self-pay, respite care, etc.

3,562 

Subtotal

$

340,801 

Medicare cap adjustment

(125)

Implicit price concessions

(4,302)

Room and board, net

(2,646)

Net revenue

$

333,728 

The composition of patient care service revenue by payor and level of care for the quarter ended September 30, 2022 is as follows (in thousands):

Medicare

Medicaid

Commercial

Total

Routine home care

$

239,670 

$

10,822 

$

5,761 

$

256,253 

Continuous care

17,083 

787 

730 

18,600 

Inpatient care

21,391 

1,838 

1,297 

24,526 

$

278,144 

$

13,447 

$

7,788 

$

299,379 

All other revenue - self-pay, respite care, etc.

3,240 

Subtotal

$

302,619 

Medicare cap adjustment

(618)

Implicit price concessions

(2,952)

Room and board, net

(2,513)

Net revenue

$

296,536 


-11-


The composition of patient care service revenue by payor and level of care for nine months ended September 30, 2023 is as follows (in thousands):

Medicare

Medicaid

Commercial

Total

Routine home care

$

781,639 

$

33,143 

$

17,772 

$

832,554 

Continuous care

58,071 

2,384 

2,599 

63,054 

Inpatient care

73,402 

6,477 

4,433 

84,312 

$

913,112 

$

42,004 

$

24,804 

$

979,920 

All other revenue - self-pay, respite care, etc.

9,738 

Subtotal

$

989,658 

Medicare cap adjustment

(5,625)

Implicit price concessions

(10,650)

Room and board, net

(8,317)

Net revenue

$

965,066 

The composition of patient care service revenue by payor and level of care for the nine months ended September 30, 2022 is as follows (in thousands):

Medicare

Medicaid

Commercial

Total

Routine home care

$

722,035 

$

32,848 

$

16,637 

$

771,520 

Continuous care

53,103 

2,337 

2,277 

57,717 

Inpatient care

66,412 

5,608 

3,694 

75,714 

$

841,550 

$

40,793 

$

22,608 

$

904,951 

All other revenue - self-pay, respite care, etc.

9,461 

Subtotal

$

914,412 

Medicare cap adjustment

(5,118)

Implicit price concessions

(8,992)

Room and board, net

(6,796)

Net revenue

$

893,506 

Roto-Rooter

Roto-Rooter provides plumbing, drain cleaning, excavation, water restoration and other related services to both residential and commercial customers primarily in the United States. Services are provided through a network of company-owned branches, independent contractors and franchisees. Service revenue for Roto-Rooter is reported at the amount that reflects the ultimate consideration we expect to receive in exchange for providing services.

Roto-Rooter owns and operates branches focusing mainly on large population centers in the United States. Roto-Rooter’s primary lines of business in company-owned branches consist of plumbing, sewer and drain cleaning, excavation and water restoration. For purposes of ASC 606 analysis, plumbing, sewer and drain cleaning, and excavation have been combined into one portfolio and are referred to as “short-term core services”. Water restoration is analyzed as a separate portfolio. The following describes the key characteristics of these portfolios:

Short-term Core Services are plumbing, drain and sewer cleaning and excavation services. These services are provided to both commercial and residential customers. The duration of services provided in this category range from a few hours to a few days. There are no significant warranty costs or on-going obligations to the customer once a service has been completed. For residential customers, payment is received at the time of job completion before the Roto-Rooter technician leaves the residence. Commercial customers may be granted credit subject to internally designated authority limits and credit check guidelines. If credit is granted, payment terms are generally 30 days or less.

Each job in this category is a distinct service with a distinct performance obligation to the customer. Revenue is recognized at the completion of each job. Variable consideration consists of pre-invoice discounts and post-invoice discounts. Pre-invoice discounts are given in the form of coupons or price concessions. Post-invoice discounts consist of credit memos generally granted to resolve customer service issues. Variable consideration is estimated based on historical activity and recorded at the time service is completed.

Water Restoration Services involve the remediation of water and humidity after a flood. These services are provided to both commercial and residential customers. The duration of services provided in this category generally ranges from 3 to 5 days. There are no significant warranties or on-going obligations to the customer once service has been completed. The majority of these services are

-12-


paid by the customer’s insurance company. Variable consideration relates primarily to allowances taken by insurance companies upon payment. Variable consideration is estimated based on historical activity and recorded at the time service is completed.

For both short-term core services and water restoration services, Roto-Rooter satisfies its performance obligation at a point in time. The services provided generally involve fixing plumbing, drainage or flood-related issues at the customer’s property. At the time service is complete, the customer acknowledges its obligation to pay for service and its satisfaction with the service performed. This provides evidence that the customer has accepted the service and Roto-Rooter is now entitled to payment. As such, Roto-Rooter recognizes revenue for these services upon completion of the job and receipt of customer acknowledgement. Roto-Rooter’s performance obligations for short-term core services and water restoration services relate to contracts with an expected duration of less than a year. Therefore, Roto-Rooter has elected to apply the optional exception provided in ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Roto-Rooter does not have significant unsatisfied or partially unsatisfied performance obligations at the time of initial revenue recognition for short-term core or water restoration services.

Roto-Rooter owns the rights to certain territories and contracts with independent third-parties to operate the territory under Roto-Rooter’s registered trademarks (“Independent Contractors”). Such contracts are for a specified term but cancellable by either party without penalty with 90 days’ advance notice. Under the terms of these arrangements, Roto-Rooter provides certain back office support and advertising along with a limited license to use Roto-Rooter’s registered trademarks. The Independent Contractor is responsible for all day-to-day management of the business including staffing decisions and pricing of services provided. All performance obligations of Roto-Rooter cease at the termination of the arrangement.

Independent Contractors pay Roto-Rooter a standard fee calculated as a percentage of their cash collection from weekly sales. The primary value for the Independent Contractors under these arrangements is the right to use Roto-Rooter’s registered trademarks. Roto-Rooter recognizes revenue from Independent Contractors over-time (weekly) as the Independent Contractor’s labor sales are completed and payment from customers are received. Payment from Independent Contractors is also received on a weekly basis. The use of Roto-Rooter’s registered trademarks and advertising provides immediate value to the Independent Contractor as a result of Roto-Rooter’s nationally recognized brand. Therefore, over-time recognition provides the most faithful depiction of the transfer of services as the customer simultaneously receives and consumes the benefits provided. There is no significant variable consideration related to these arrangements.

Roto-Rooter has licensed the rights to operate under Roto-Rooter’s registered trademarks in other territories to franchisees. Each such contract is for a 10 year term but cancellable by Roto-Rooter for cause with 60 day advance notice without penalty. The franchisee may cancel the contract for any reason with 60 days advance notice without penalty. Under the terms of the contract, Roto-Rooter provides national advertising and consultation on various aspects of operating a Roto-Rooter business along with the right to use Roto-Rooter’s registered trademarks. The franchisee is responsible for all day- to-day management of the business including staffing decisions, pricing of services provided and local advertising spend and placement. All performance obligations of Roto-Rooter cease at the termination of the arrangement.

Franchisees pay Roto-Rooter a standard monthly fee based on the population within the franchise territory. The standard fee is revised on a yearly basis based on changes in the Consumer Price Index for All Urban Consumers. The primary value for the franchisees under this arrangement is the right to use Roto-Rooter’s registered trademarks. Roto-Rooter recognizes revenue from franchisees over-time (monthly). Payment from franchisees is also received on a monthly basis. The use of Roto-Rooter’s registered trademarks and advertising provides immediate value to the franchisees as a result of Roto-Rooter’s nationally recognized brand. Therefore, over-time recognition provides the most faithful depiction of the transfer of services as the customer simultaneously receives and consumes the benefits provided. There is no significant variable consideration related to these arrangements.


-13-


The composition of disaggregated revenue for the third quarter is as follows (in thousands):

September 30,

2023

2022

Drain cleaning

$

59,164 

$

62,764 

Plumbing

49,113 

48,737 

Excavation

56,904 

54,164 

Other

334 

193 

Subtotal - short term core

165,515 

165,858 

Water restoration

45,435 

43,645 

Independent contractors

20,509 

20,474 

Franchisee fees

1,457 

1,559 

Other

4,246 

4,030 

Gross revenue

237,162 

235,566 

Implicit price concessions and credit memos

(6,358)

(5,630)

Net revenue

$

230,804 

$

229,936 

The composition of disaggregated revenue for the first nine months is as follows (in thousands):

September 30,

2023

2022

Drain cleaning

$

186,016 

$

193,983 

Plumbing

148,285 

145,294 

Excavation

174,032 

164,898 

Other

711 

513 

Subtotal - short term core

509,044 

504,688 

Water restoration

141,176 

127,678 

Independent contractors

65,684 

62,897 

Franchisee fees

4,195 

4,246 

Other

13,292 

12,462 

Gross revenue

733,391 

711,971 

Implicit price concessions and credit memos

(19,952)

(17,168)

Net revenue

$

713,439 

$

694,803 

3.    Segments

Service revenues and sales by business segment are shown in Note 2. After-tax income/(loss) by business segment are as follows (in thousands):

Three months ended September 30,

Nine months ended September 30,

2023

2022

2023

2022

VITAS

$

44,331 

$

26,086 

$

95,223 

$

97,779 

Roto-Rooter

50,327 

47,586 

142,354 

138,595 

Total

94,658 

73,672 

237,577 

236,374 

Corporate

(19,700)

(16,799)

(55,121)

(48,876)

Net income

$

74,958 

$

56,873 

$

182,456 

$

187,498 

We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”.

 

-14-


4.    Earnings per Share

Earnings per share (“EPS”) are computed using the weighted average number of shares of capital stock outstanding. Earnings and diluted earnings per share are computed as follows (in thousands, except per share data):

Net Income

For the Three Months Ended September 30,

Income

Shares

Earnings per Share

2023

Earnings

$

74,958

15,075

$

4.97

Dilutive stock options

-

82

Nonvested stock awards

-

43

Diluted earnings

$

74,958

15,200

$

4.93

2022

Earnings

$

56,873

14,888

$

3.82

Dilutive stock options

-

118

Nonvested stock awards

-

36

Diluted earnings

$

56,873

15,042

$

3.78

Net Income

For the Nine Months Ended September 30,

Income

Shares

Earnings per Share

2023

Earnings

$

182,456 

15,034 

$

12.14 

Dilutive stock options

-

98 

Nonvested stock awards

-

46 

Diluted earnings

$

182,456 

15,178 

$

12.02 

2022

Earnings

$

187,498 

14,935 

$

12.55 

Dilutive stock options

-

140 

Nonvested stock awards

-

39 

Diluted earnings

$

187,498 

15,114 

$

12.41 

For the three and nine months ended September 30, 2023, there were 309,336 stock options excluded from the computation of dilutive earnings per share because they would have been anti-dilutive.

For the three and nine months ended September 30, 2022, there were 592,000 and 593,000, respectively, stock options excluded from the computation of dilutive earnings per share because they would have been anti-dilutive.

5.    Long-Term Debt and Lines of Credit

On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a five-year $450.0 million revolver as well as a five-year $100.0 million term loan. Principal payments of $1.25 million on the term loan are due on the last day of each fiscal quarter, with a final payment due at the end of the agreement. The 2022 Credit Facilities have a floating interest rate that is generally the secured overnight financing rate (“SOFR”) plus an additional tiered rate which varies based on our current leverage ratio. As of September 30, 2023, the interest rate is SOFR plus 100 basis points. The 2022 Credit Facilities include an expansion feature that provides the Company the opportunity to increase its revolver and or term loan by an additional $250.0 million.

We made prepayments totaling $75.0 million in the first quarter of 2023, on the $100.0 million term loan. We paid the remaining balance of $21.3 million on April 28, 2023. There were no prepayment penalties associated with this repayment. There are no significant deferred debt issuance costs capitalized related to the term loan. This prepayment reduced the total borrowing capacity of the 2022 Credit Facilities from $550.0 million to $450.0 million.

-15-


The 2022 Credit Facilities contain the following quarterly financial covenants effective as of September 30, 2023:

Description

Requirement

Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA)

< 3.50 to 1.00

Interest Coverage Ratio (Consolidated Adj. EBITDA/Consolidated Interest Expense)

> 3.00 to 1.00

We are in compliance with all debt covenants as of September 30, 2023. We have issued $45.3 million in standby letters of credit as of September 30, 2023, mainly for insurance purposes. Issued letters of credit reduce our available credit under the 2022 Credit Facilities. As of September 30, 2023, we have approximately $404.8 million of unused lines of credit available and eligible to be drawn down under the revolving credit facility.

6.    Other Income/(Expense) – Net

Other income/(expense) – net comprises the following (in thousands):

 

Three months ended September 30,

Nine months ended September 30,

2023

2022

2023

2022

Market value adjustment on assets held in

deferred compensation trust

$

4,257 

$

(3,176)

$

5,441 

$

(12,196)

Interest income

2,600 

62 

2,863 

288 

Other-net

2 

(1)

61 

1 

Total other income/(expense) - net

$

6,859 

$

(3,115)

$

8,365 

$

(11,907)

 

7.    Leases

Chemed and each of its operating subsidiaries are service companies. As such, real estate leases comprise the largest lease obligation (and conversely, right of use asset) in our lease portfolio. VITAS has leased office space, as well as space for inpatient units (“IPUs”) and/or contract beds within hospitals. Roto-Rooter mainly has leased office space. Our leases have remaining terms of under 1 year to 10 years, some of which include options to extend the lease for up to 5 years, and some of which include options to terminate the lease within 1 year.

Roto-Rooter purchases equipment and leases it to certain of its Independent Contractors. We analyzed these leases in accordance with ASC 842 and determined they are operating leases. As a result, Roto-Rooter capitalizes the equipment underlying these leases, depreciates the equipment and recognizes rental income.

We do not currently have any finance leases, therefore all lease information disclosed is related to operating leases.

The components of balance sheet information related to leases were as follows:

September 30,


December 31,

2023

2022

Assets

Operating lease assets

$

123,353 

$

135,662 

Liabilities

Current operating leases

37,615 

38,996 

Noncurrent operating leases

99,346 

110,513 

Total operating lease liabilities

$

136,961 

$

149,509 


-16-


The components of lease expense for the third quarter are as follows (in thousands):

Three months ended September 30,

2023

2022

Lease Expense (a)

Operating lease expense

$

14,999 

$

12,936 

Sublease income

(23)

(45)

Net lease expense

$

14,976 

$

12,891 

The components of lease expense for the first nine months are as follows (in thousands):

Nine months ended September 30,

2023

2022

Lease Expense (a)

Operating lease expense

$

44,811 

$

39,230 

Sublease income

(70)

(136)

Net lease expense

$

44,741 

$

39,094 

(a)Includes short-term leases and variable lease costs, which are immaterial. Included in both cost of services provided and goods sold and selling, general and administrative expenses.

The components of cash flow information related to leases were as follows:

Nine months ended September 30,

2023

2022

Cash paid for amounts included in the measurement of lease liabilities

Operating cash flows from leases

$

37,352 

$

37,650 

Leased assets obtained in exchange for new operating lease liabilities

$

21,630 

$

41,855 

Weighted Average Remaining Lease Term at September 30, 2023

Operating leases

4.39

years

Weighted Average Discount Rate at September 30, 2023

Operating leases

2.87

%

Maturity of Operating Lease Liabilities (in thousands)

2023

$

11,649 

2024

41,093 

2025

33,289 

2026

26,016 

2027

15,005 

Thereafter

19,234 

Total lease payments

$

146,286 

Less: interest

(9,325)

Total liability recognized on the balance sheet

$

136,961 

For leases commencing prior to April 2019, minimum rental payments exclude payments to landlords for real estate taxes and common area maintenance. Operating lease payments include $2.7 million related to extended lease terms that are reasonably certain of being exercised and exclude $201,000 of lease payments for leases signed but not yet commenced.

-17-


8.    Stock-Based Compensation Plans

On February 17, 2023, the Compensation/Incentive Committee of the Board of Directors (“CIC”) granted 6,078 Performance Stock Units (“PSUs”) that vest contingent upon the achievement of certain total shareholder return (“TSR”) targets as compared to the TSR of a group of peer companies for the three-year period ending December 31, 2025, the date at which such awards vest. The cumulative compensation cost of the TSR-based PSU award to be recorded over the three-year service period is $5.1 million.

On February 17, 2023, the CIC also granted 6,078 PSUs that vest contingent upon the achievement of certain earnings per share (“EPS”) targets for the three-year period ending December 31, 2025. At the end of each reporting period, the Company estimates the number of shares that it believes will ultimately be earned and records the corresponding expense over the service period of the award. We currently estimate the cumulative compensation cost of the EPS-based PSUs to be recorded over the three-year service period is $4.2 million.  

9.    Retirement Plans

All of the Company’s plans that provide retirement and similar benefits are defined contribution plans. These expenses include the impact of market gains and losses on assets held in deferred compensation plans and are recorded in selling, general and administrative expenses. Net gains for the Company’s retirement and profit-sharing plans, excess benefit plans and other similar plans are as follows (in thousands):

Three months ended September 30,

Nine months ended September 30,

2023

2022

2023

2022

$

8,551

$

2,091

$

19,974

$

5,647

 

10.    Legal and Regulatory Matters

The VITAS segment of the Company’s business operates in a heavily-regulated industry. As a result, the Company is subjected to inquiries and investigations by various government agencies, which can result in penalties including repayment obligations, funding withholding, or debarment, as well as to lawsuits, including qui tam actions. The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware. Other than as described below, it is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or reasonably estimable.

Regulatory Matters and Litigation

On October 30, 2017, the Company entered into a settlement agreement to resolve civil litigation under the False Claims Act brought by the United States Department of Justice (“DOJ”) on behalf of the OIG and various relators concerning VITAS, filed in the U.S. District Court of the Western District of Missouri. The Company denied any violation of law and agreed to settlement without admission of wrongdoing.

In connection with the settlement, VITAS and certain of its subsidiaries entered into a corporate integrity agreement (“CIA”) on October 30, 2017 with a five-year term. The CIA formalized various aspects of VITAS’ already existing Compliance Program and contained requirements designed to document compliance with federal healthcare program requirements. On June 22, 2023, the OIG confirmed that VITAS has satisfied its requirements under the CIA and that the CIA was concluded.

On October 16, 2020, VITAS received a Civil Investigative Demand (“CID”) issued by the U.S. Department of Justice (“DOJ”) pursuant to the False Claims Act concerning allegations of the submission of false claims for hospice services for which reimbursement was sought from federal healthcare programs, including Medicare. The CID requested information regarding 32 patients from our Florida operations. On November 30, 2022, VITAS received a Letter of Declination from the DOJ, informing VITAS that the United States was declining to intervene in this case giving rise to the CID, United States Ex. Rel. O’Keefe v VITAS Healthcare Corporation, et al. that was unsealed on November 15, 2022. On April 6, 2023, the relator dismissed the case, without prejudice, with the consent of the United States.

VITAS is one of a group of hospice providers selected by the OIG’s Office of Audit Services (“OAS”) for inclusion in an audit of the provision of elevated level-of-care hospice services. On July 14, 2022, VITAS received the final audit report from OAS. Per this report, the OAS audit examined VITAS inpatient and continuous care claims for the period April 2017 to March 2019. The audit covered a total population of 50,850 claims representing total Medicare reimbursement of $210.0 million during this two-year time period. From this population, OAS selected 100 claims, representing $688,000 of reimbursement, for detailed review. The final OAS audit report includes a series of recommendations, including that VITAS repay approximately $140.0 million of the $210.0 million VITAS received from Medicare for hospice services during this two-year period, despite the fact that at the time of the release of the

-18-


results of the audit, many of the disputed claims were time-barred from being challenged. VITAS believes that the OAS audit process and related final report contains significant flaws including its methodology, medical reviews, technical reviews, proposed extrapolation methodology, and contravenes the “reasonable physician standard” set forth in the appliable Aseracare precedent.

On August 29, 2022, six weeks subsequent to the OAS finalizing its audit, VITAS received a demand letter from its Medicare Administrative Contractor (“MAC”) seeking repayment of $50.3 million. This demand letter is $90.0 million lower than the final OAS audit recommendation, as a significant portion of the 100 claims reviewed are closed pursuant to applicable law and ineligible to be reopened. VITAS timely filed its initial appeal of the overpayment decision and deposited $50.3 million under the “Immediate Recoupment” process to preserve its appeal rights. To date, VITAS has been refunded $2.5 million of the amount deposited and continues to appeal the remaining claims. The amount deposited has been recorded as an “other long-term asset” in the consolidated balance sheets, as detailed in Note 13.

Regardless of the outcome of any of the preceding matters, dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, withholding of governmental funding, diversion of management time, and related publicity. Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.

11.    Concentration of Risk

As of September 30, 2023, and December 31, 2022, approximately 73% and 64%, respectively, of VITAS’ total accounts receivable balance were from Medicare and 21% and 29%, respectively, of VITAS’ total accounts receivable balance were due from various state Medicaid or managed Medicaid programs. Combined accounts receivable from Medicare, Medicaid, and managed Medicaid represent approximately 79% of the consolidated net accounts receivable in the accompanying consolidated balance sheets as of September 30, 2023.

VITAS has a pharmacy services contract with one service provider for specified pharmacy services related to its hospice operations. Similarly, VITAS obtains the majority of its medical supplies from a single vendor. A large majority of VITAS’ pharmaceutical and medical supplies purchases are from these vendors. The pharmaceutical and medical supplies purchased by VITAS are available through many providers in the United States. However, a disruption from VITAS’ main service providers could adversely impact VITAS’ operations, including temporary logistical challenges and increased cost associated with getting medication and medical supplies to our patients.

 

12.    Cash Overdrafts and Cash Equivalents

There are $16.2 million in cash overdrafts payable included in accounts payable at September 30, 2023. There were no cash overdrafts payable included in accounts payable at December 31, 2022.

From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. In the third quarter of 2023, Chemed began investing excess cash in a money market fund holding US Treasuries. Deposits and withdrawals are made daily, based on the Company’s excess cash balance. There are no penalties associated with withdrawals. The accounts bear interest at a normal market rate.

13.     Other Assets

Other assets comprise the following (in thousands):

 

September 30,

December 31,

2023

2022

Deposit with OAS

$

47,756 

$

50,274 

Cash surrender value life insurance

3,647 

3,636 

Noncurrent advances and deposits

2,223 

2,368 

Other long-term receivable

1,718 

1,826 

Deferred debt costs

1,226 

1,703 

$

56,570 

$

59,807 


-19-


14.     Other Current Liabilities

September 30,

December 31,

2023

2022

Healthcare worker retention bonus

$

14,638 

$

19,634 

Medicare Cap

10,870 

14,380 

Accrued advertising

2,899 

2,516 

All other

26,941 

24,474 

$

55,348 

$

61,004 

There are no individual amounts exceeding 5% of the total current liabilities in the “all other” line item for either period presented.

15.    Financial Instruments

FASB’s authoritative guidance on fair value measurements defines a hierarchy which prioritizes the inputs in fair value measurements. Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities. Level 2 measurements use significant other observable inputs. Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions. In recording the fair value of assets and liabilities, companies must use the most reliable measurement available.

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of September 30, 2023 (in thousands):

Fair Value Measure

Carrying Value

Quoted Prices in Active Markets for Identical Assets (Level 1)

Significant Other Observable Inputs (Level 2)

Significant Unobservable Inputs (Level 3)

Investments of deferred compensation plans held in trust

$

104,410 

$

104,410 

$

-

$

-

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of December 31, 2022 (in thousands):

Fair Value Measure

Carrying Value

Quoted Prices in Active Markets for Identical Assets (Level 1)

Significant Other Observable Inputs (Level 2)

Significant Unobservable Inputs (Level 3)

Investments of deferred compensation plans held in trust

$

93,196 

$

93,196 

$

-

$

-

Long-term debt and current portion of long-term debt

97,500 

-

97,500 

-

For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments. As further described in Note 5, our outstanding long-term debt has a floating interest rate that is reset at short-term intervals, generally 30 or 60 days. The interest rate we pay also includes an additional amount based on our current leverage ratio. As such, we believe our borrowings reflect significant nonperformance risks, mainly credit risk. Based on these factors, we believe the fair value of our long-term debt approximates its carrying value.


-20-


16.    Capital Stock Repurchase Plan Transactions

We repurchased the following capital stock:

Three months ended September 30,

Nine months ended September 30,

2023

2022

2023

2022

Total cost of repurchased shares (in thousands)

$

14,344 

$

23,884 

$

27,769 

$

101,098 

Shares repurchased

28,457 

50,000 

53,457 

207,500 

Weighted average price per share

$

504.07 

$

477.68 

$

519.46 

$

487.22 

In May and November 2021, the Board of Directors authorized a total of $600.0 million for additional stock repurchase under Chemed’s existing share repurchase program. We currently have $60.1 million of authorization remaining under this share repurchase plan.

17.    Acquisitions

On June 1, 2023 Roto-Rooter completed the acquisition of one franchise in South Carolina for $305,000 in cash. On September 26, 2023 Roto-Rooter completed the acquisition of one franchise in Georgia for $3.689 million in cash.

In 2022, VITAS purchased the hospice assets of one Florida provider for $1.24 million in cash. Roto-Rooter completed the acquisition of three franchises and the related assets in New Jersey for a total of $2.29 million in cash.

Goodwill is assessed for impairment on a yearly basis as of October 1. All goodwill recognized is deductible for tax purposes.

Shown below is movement in Goodwill (in thousands):

VITAS

Roto-Rooter

Total

Balance at December 31, 2022

$

334,063 

$

247,232 

$

581,295 

Business combinations

-

3,682 

3,682 

Balance at September 30, 2023

$

334,063 

$

250,914 

$

584,977 


-21-


Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, Independent Contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The vast majority of the Company’s operations are located in the United States. As both operations are service companies, our employees are the most critical resource of the Company. We have very little exposure related to customers, vendors, or employees in other regions of the world.

The following is a summary of the key operating results (in thousands except per share amounts):

Three months ended September 30,

Nine months ended September 30,

2023

2022

2023

2022

Service revenues and sales

$

564,532 

$

526,472 

$

1,678,505 

$

1,588,309 

Net income

$

74,958 

$

56,873 

$

182,456 

$

187,498 

Diluted EPS

$

4.93 

$

3.78 

$

12.02 

$

12.41 

Adjusted net income

$

80,866 

$

64,116 

$

207,701 

$

209,986 

Adjusted diluted EPS

$

5.32 

$

4.26 

$

13.68 

$

13.89 

Adjusted EBITDA

$

115,836 

$

99,169 

$

312,253 

$

320,283 

Adjusted EBITDA as a % of revenue

20.5 

%

18.8 

%

18.6 

%

20.2 

%

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 35-37.

Starting with the September 30, 2023 quarter, Chemed is no longer excluding the cost of the Retention Program when presenting non-GAAP operating metrics in current or prior periods.

In the September 30, 2023 quarter, there is zero expense related to the Retention Program. In the September 30, 2022 quarter, the pretax and after-tax Retention Program expense was $9.6 million and $7.1 million, respectively.

For the nine months ended September 30, 2023 pretax and after-tax expense for the retention program is $23.8 million and $18.0 million, respectively. For the nine months ended September 30, 2022 pretax and after-tax expense for the Retention Program was $9.6 million and $7.1 million, respectively

For the three months ended September 30, 2023, the increase in consolidated service revenues and sales was driven by a 12.5% increase at VITAS and a 0.4% increase at Roto-Rooter. The increase in service revenues at Roto-Rooter was driven mainly by an increase in plumbing, excavation and water restoration offset by a decrease in drain cleaning. The increase in service revenues at VITAS is comprised primarily of a 9.4% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.7%. Acuity mix shift positively impacted revenue growth 24-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 20-basis points.

For the nine months ended September 30, 2023, the increase in consolidated service revenues and sales was driven by an 8.0% increase at VITAS and a 2.7% increase at Roto-Rooter. The increase in service revenues at Roto-Rooter was driven mainly by an increase in plumbing, excavation, and water restoration, offset by a decrease in drain cleaning. The increase in service revenues at VITAS is comprised primarily of a 6.2% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.8%, partially offset by 100-basis points as a result of CMS reimplementing sequestration that was suspended at the start of the pandemic in 2020. Acuity mix shift had minimal impact in the quarter when compared to the prior year revenue and level-of-care mix.

-22-


The pandemic resulted in a significant shortage of licensed healthcare workers industry wide. VITAS has not been immune to this shortage. As a result, on July 1, 2022, VITAS implemented a hiring and retention bonus program for its licensed healthcare workers. It is a temporary program intended to help VITAS attract and retain licensed healthcare workers in light of the pandemic- induced healthcare worker shortage. An eligible employee must continue in employment for a period of one-year from July 1st to receive a bonus. Additionally, employees hired between July 1, 2022 and June 30, 2023 are eligible if they continue employment for a one-year period from their hire date. A total of $43.4 million has been accrued since the start of the program. A payment of $28.6 million was made in July 2023 related to the employed workers as of July 1, 2022. The remaining accrued amount will be paid over the following four quarters. See page 38 for additional VITAS operating metrics.

While significant continuing issues related to the COVID-19 pandemic appear to be over or materially mitigated, we will continue to monitor any impact on our business including employees, customers, patients, and vendors.

VITAS 2023 revenue, prior to Medicare Cap, is estimated to increase 9.3% to 9.5% when compared to 2022. Forecasted revenue growth is negatively impacted by 75-basis points as a result of the sequestration relief in the first half of 2022 compared to a full year of sequestration in 2023. ADC is estimated to increase 7.3% to 7.5%. Full year adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 15.4% to 15.7%. The total pretax cost of the Retention Program in 2023 is estimated at $23.8 million, reducing adjusted EBITDA margin by 180-basis points. We are currently estimating $8.0 million for Medicare Cap billing limitations in calendar year 2023.

Roto-Rooter is forecasted to achieve full-year 2023 revenue growth of 1.6% to 2.0%. Roto-Rooter’s adjusted EBITDA margin for 2023 is expected to be 28.4% to 28.6%.

Based upon the above, full-year 2023 earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, and other discrete items, is estimated to be in the range of $19.82 to $20.02. This guidance includes $1.18 per share of after-tax costs related to the 2023 portion of the Retention Program.

This revised 2023 guidance compares to previous guidance, as recast to no longer exclude costs associated with the Retention Program, of $18.72 to $18.92. Current 2023 guidance assumes an effective corporate tax rate on adjusted earnings of 23.6% and a diluted share count of 15.2 million shares. Chemed’s 2022 adjusted earnings per diluted share was $18.78, including $0.97 per share for costs associated with the 2022 portion of the Retention Program.

On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a five-year $450.0 million revolver as well as a five-year $100.0 million term loan. Principal payments of $1.25 million on the term loan are due on the last day of each fiscal quarter, with a final payment due at the end of the agreement. The 2022 Credit Facilities have a floating interest rate that is generally SOFR plus an additional tiered rate which varies based on our current leverage ratio. As of September 30, 2023, the interest rate is SOFR plus 100 basis points. The 2022 Credit Facilities include an expansion feature that provides the Company the opportunity to increase its revolver and/or term loan by an additional $250.0 million.

We made prepayments totaling $75.0 million in the first quarter of 2023, on the $100.0 million term loan. We paid the remaining balance of $21.3 million on April 28, 2023. There were no prepayment penalties associated with this repayment. This prepayment reduced the total borrowing capacity of the 2022 Credit Facilities from $550.0 million to $450.0 million.

We have issued $45.3 million in standby letters of credit as of September 30, 2023, mainly for insurance purposes. Issued letters of credit reduce our available credit under the 2022 Credit Facilities. As of September 30, 2023, we have approximately $404.8 million of unused lines of credit available and are eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future.

Financial Condition

Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2022 to September 30, 2023 include the following:

A $28.6 million increase in accounts receivable due to timing of receipts. See discussion below.

A $11.2 million increase in investments of deferred compensation plans due to market valuation gains. This resulted in a similar increase in the liability associated with deferred compensation plans.

A $12.3 million decrease in lease right of use asset due to lease amortization.

-23-


A $14.6 million increase in accounts payable due to timing of payments.

A $12.5 million decline in accrued compensation due to payment of 2022 bonuses in the first quarter of 2023.

A $97.5 million decrease in total long-term debt due to early repayments.

A $12.5 million decrease in lease liabilities due to lease amortization.

Net cash provided by operating activities increased $12.0 million from September 30, 2022 to September 30, 2023. The main driver is an increase of $44.0 million attributable to changes in accounts receivable, offset by a decrease of $33.8 million of outflows related to other assets, driven primarily by the OAS deposit made in 2022. Significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $42.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two-year period, as cash flow variations in one year are offset in the following year.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

Commitments and Contingencies

Collectively, the terms of the 2022 Credit Facilities require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of September 30, 2023 and anticipate remaining in compliance throughout the foreseeable future.

We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 10 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.


-24-


Results of Operations

Three months ended September 30, 2023 versus 2022 - Consolidated Results

Our service revenues and sales for the third quarter of 2023 increased 7.2% versus services and sales revenues for the third quarter of 2022. Of this increase, a $37.2 million increase was attributable to VITAS, and an $868,000 increase was attributable to Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):

Three months ended September 30,

Increase/(Decrease)

2023

2022

Percent

VITAS

Routine homecare

$

287,389 

$

256,253 

12.2 

Continuous care

22,032 

18,600 

18.5 

General inpatient

27,818 

24,526 

13.4 

Other

3,562 

3,240 

9.9 

Subtotal

340,801 

302,619 

12.6 

Medicare cap adjustment

(125)

(618)

79.8 

Room and board - net

(2,646)

(2,513)

(5.3)

Implicit price concessions

(4,302)

(2,952)

(45.7)

Net revenue

$

333,728 

$

296,536 

12.5 

Roto-Rooter

Drain cleaning

$

59,164 

$

62,764 

(5.7)

Plumbing

49,113 

48,737 

0.8 

Excavation

56,904 

54,164 

5.1 

Other

334 

193 

73.1 

Subtotal - short term core

165,515 

165,858 

(0.2)

Water restoration

45,435 

43,645 

4.1 

Independent contractors

20,509 

20,474 

0.2 

Outside franchisee fees

1,457 

1,559 

(6.5)

Other

4,246 

4,030 

5.4 

Gross revenue

237,162 

235,566 

0.7 

Implicit price concessions

(6,358)

(5,630)

(12.9)

Net revenue

230,804 

229,936 

0.4 

Total Revenues

$

564,532 

$

526,472 

7.2 

Days of care at VITAS during the quarters were as follows:

Three months ended September 30,

Increase/(Decrease)

2023

2022

Percent

Routine homecare

1,391,377 

1,271,678 

9.4 

Nursing home

287,785 

264,407 

8.8 

Respite

7,292 

6,635 

9.9 

Subtotal routine homecare and respite

1,686,454 

1,542,720 

9.3 

General inpatient

25,493 

23,435 

8.8 

Continuous care

23,071 

20,097 

14.8 

Total days of care

1,735,018 

1,586,252 

9.4 

The increase in service revenues at VITAS is comprised primarily of a 9.4% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.7%. Acuity mix shift positively impacted revenue growth 24-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 20-basis points.

The increase in plumbing revenues for the third quarter of 2023 versus 2022 is attributable to a 7.9% increase in price and service mix shift offset by a 7.1% decrease in job count. The decrease in drain cleaning revenues for the third quarter of 2023 versus 2022 is attributable to a 6.6% increase in price and service mix offset by a 12.3% decrease in job count. The decline in drain cleaning

-25-


volume is mainly the result of macro-economic consumer caution, as seen by many consumer-facing businesses. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues. As a result, the 5.1% increase in excavation revenue and the 4.1% increase in water restoration revenue are mainly a function of the numbers and size of drain cleaning issues we encounter on a quarterly basis.

The consolidated gross margin was 35.8% in the third quarter of 2023 as compared with 34.1% in the third quarter of 2022. On a segment basis, VITAS’ gross margin was 24.0% in the third quarter of 2023 as compared with 19.1%, in the third quarter of 2022. The increase in gross margin at VITAS is mostly the result of increased revenues and the expiration of the licensed healthcare worker retention bonus program. The Roto-Rooter segment’s gross margin was 52.9% for the third quarter of 2023 as compared with 53.4% in the third quarter of 2022. This decline was mainly the result of relatively flat revenue and increased advertising cost.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Three months ended September 30,

2023

2022

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts

$

91,792 

$

85,118 

Impact of market value adjustments related to assets held in deferred compensation trusts

4,257 

(3,176)

Long-term incentive compensation

3,553 

2,050 

Total SG&A expenses

$

99,602 

$

83,992 

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the third quarter of 2023 were up 7.8% when compared to third quarter of 2022. This increase was mainly a result of an increase in variable selling and general administrative expenses and salary increases.

Other income/(expense) – net comprise (in thousands):

Three months ended September 30,

2023

2022

Market value adjustment on assets held in deferred compensation trusts

$

4,257 

$

(3,176)

Interest income

2,600 

62 

Other

(1)

Total other income/(expense) - net

$

6,859 

$

(3,115)

From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. In the third quarter of 2023, Chemed began investing excess cash in a money market fund holding US Treasuries. Deposits and withdrawals are made daily, based on the Company’s excess cash balance. There are no penalties associated with withdrawals. The accounts bear interest at a normal market rate.

Our effective tax rate reconciliation is as follows (in thousands):

Three months ended September 30,

2023

2022

Income tax provision calculated at the statutory federal rate

$

19,586 

$

16,059 

Stock compensation tax benefits

(225)

(450)

State and local income taxes

2,105 

2,877 

Effect of rate change on deferred tax

(4,241)

-

Other--net

1,082 

1,112 

Income tax provision

$

18,307 

$

19,598 

Effective tax rate

19.6 

%

25.6 

%

During the third quarter of 2023, the Company recognized a tax benefit from realignment of its state and local corporate tax structure based on the location of operating resources and profitability by business segment. This benefit includes a reduction in current state and local tax expense and a one time benefit of $4.2 million in reduction of deferred tax liabilities reflecting the lower tax rates.


-26-


Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

Three months ended September 30,

2023

2022

VITAS

Impact of deferred rate tax change

$

1,772 

$

-

Roto-Rooter

Impact of deferred rate tax change

3,559 

-

Amortization of reacquired franchise agreements

(1,954)

(1,729)

Litigation settlements

(286)

-

Corporate

Stock option expense

(4,924)

(4,060)

Long-term incentive compensation

(3,210)

(1,836)

Impact of deferred rate tax change

(1,090)

-

Excess tax benefits on stock compensation

225 

450 

Direct costs related to COVID-19

-

(68)

Total

$

(5,908)

$

(7,243)

Three months ended September 30, 2023 versus 2022 - Segment Results

Net income/(loss) for the third quarter of 2023 versus the third quarter of 2022 by segment (in thousands):

Three months ended September 30,

2023

2022

VITAS

$

44,331 

$

26,086 

Roto-Rooter

50,327 

47,586 

Corporate

(19,700)

(16,799)

$

74,958 

$

56,873 

After-tax earnings as a percent of revenue at VITAS in the third quarter of 2023 was 13.3% as compared to 8.8% in the third quarter of 2022. VITAS’ after-tax earnings increased primarily due to increased revenues and the tax benefit from the realignment of its state and local corporate tax structure change.

Roto-Rooter’s net income was impacted in the third quarter of 2023 compared to the third quarter of 2022 primarily due to tax benefit from the realignment of its state and local corporate tax structure change After-tax earnings as a percent of revenue at Roto-Rooter in the third quarter of 2023 was 21.8%, as compared to 20.7% in the third quarter of 2022.

After-tax Corporate expenses for the third quarter of 2023 increased 17.3% when compared to 2022 due primarily to a $2.2 million increase in stock-based compensation.


-27-


Results of Operations

Nine months ended September 30, 2023 versus 2022 - Consolidated Results

Our service revenues and sales for the first nine months of 2023 increased 5.7% versus services and sales revenues for the first nine months of 2022. Of this increase, a $71.6 million increase was attributable to VITAS and a $18.6 million increase was attributable to Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):

Nine months ended September 30,

Increase/(Decrease)

2023

2022

Percent

VITAS

Routine homecare

$

832,554 

$

771,520 

7.9 

Continuous care

63,054 

57,717 

9.2 

General inpatient

84,312 

75,714 

11.4 

Other

9,738 

9,461 

2.9 

Subtotal

989,658 

914,412 

8.2 

Medicare cap adjustment

(5,625)

(5,118)

(9.9)

Room and board - net

(8,317)

(6,796)

(22.4)

Implicit price concessions

(10,650)

(8,992)

(18.4)

Net revenue

$

965,066 

$

893,506 

8.0 

Roto-Rooter

Drain cleaning

$

186,016 

$

193,983 

(4.1)

Plumbing

148,285 

145,294 

2.1 

Excavation

174,032 

164,898 

5.5 

Other

711 

513 

38.6 

Subtotal - short term core

509,044 

504,688 

0.9 

Water restoration

141,176 

127,678 

10.6 

Independent contractors

65,684 

62,897 

4.4 

Outside franchisee fees

4,195 

4,246 

(1.2)

Other

13,292 

12,462 

6.7 

Gross revenue

733,391 

711,971 

3.0 

Implicit price concessions

(19,952)

(17,168)

(16.2)

Net revenue

713,439 

694,803 

2.7 

Total Revenues

$

1,678,505 

$

1,588,309 

5.7 

Days of care at VITAS during the nine months ended September 30 were as follows:

Nine months ended September 30,

Increase/(Decrease)

2023

2022

Percent

Routine homecare

4,018,469 

3,796,954 

5.8 

Nursing home

833,112 

771,921 

7.9 

Respite

19,211 

18,098 

6.1 

Subtotal routine homecare and respite

4,870,792 

4,586,973 

6.2 

General inpatient

76,987 

71,177 

8.2 

Continuous care

65,630 

61,981 

5.9 

Total days of care

5,013,409 

4,720,131 

6.2 

The increase in service revenues at VITAS is comprised primarily of a 6.2% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.8%, partially offset by 100-basis points as a result of CMS reimplementing sequestration that was suspended at the start of the pandemic in 2020. Acuity mix shift had minimal impact in the quarter when compared to the prior year revenue and level-of-care mix.

The increase in plumbing revenues for the first nine months of 2023 versus 2022 is attributable to a 10.1% increase in price and service mix shift and 8.0% decrease in job count. Drain cleaning revenues for the first nine months of 2023 versus 2022 reflect a 7.1% increase in price and service mix shift offset by a 11.2% decrease in job count. The decline in drain cleaning volume is mainly the result of macro-economic consumer caution, as seen by many consumer-facing businesses. Excavation and water restoration jobs are

-28-


generally sold as a result of initial calls from customers regarding drain cleaning issues. As a result, the 5.5% increase in excavation revenue and the 10.6% increase in water restoration revenue are mainly a function of the numbers and size of drain cleaning issues we encounter on a quarterly basis. Independent Contractor revenue increased 4.4% due mainly to increased expansion into water restoration.

The consolidated gross margin was 34.0% in the first nine months of 2023 as compared with 35.8% in the first nine months of 2022. On a segment basis, VITAS’ gross margin was 20.2% in the first nine months of 2023 as compared with 22.3%, in the first nine months of 2022. The decrease in gross margin at VITAS is mostly the result of the $23.8 million expense recorded in the first nine months of 2023 for the licensed healthcare worker retention bonus program compared to $9.6 million recorded for the program in the first nine months of 2022. The Roto-Rooter segment’s gross margin was 52.8% for the first nine months of 2023 as compared with 53.1% in the first nine months of 2022.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Nine months ended September 30,

2023

2022

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts

$

281,426 

$

269,118 

Long-term incentive compensation

7,817 

4,877 

Impact of market value adjustments related to assets held in deferred compensation trusts

5,441 

(12,196)

Total SG&A expenses

$

294,684 

$

261,799 

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first nine months of 2023 were up 4.6% when compared to the first nine months of 2022. This increase was mainly a result of the increase in variable selling expenses and normal salary increases.

Other income/(expense) – net comprise (in thousands):

Nine months ended September 30,

2023

2022

Market value adjustment on assets held in deferred compensation trusts

$

5,441 

$

(12,196)

Interest income

2,863 

288 

Other

61 

Total other income/(expense) - net

$

8,365 

$

(11,907)

From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. In the third quarter of 2023, Chemed began investing excess cash in a money market fund holding US Treasuries. Deposits and withdrawals are made daily, based on the Company’s excess cash balance. There are no penalties associated with withdrawals. The accounts bear interest at a normal market rate.

Our effective tax rate reconciliation is as follows (in thousands):

Nine months ended September 30,

2023

2022

Income tax provision calculated at the statutory federal rate

$

49,303 

$

51,929 

Stock compensation tax benefits

(3,376)

(4,390)

State and local income taxes

7,333 

8,296 

Effect of rate change on deferred tax

(4,241)

-

Other--net

3,299 

3,946 

Income tax provision

$

52,318 

$

59,781 

Effective tax rate

22.3 

%

24.2 

%

During the third quarter of 2023, the Company recognized a tax benefit from realignment of its state and local corporate tax structure based on the location of operating resources and profitability by business segment. This benefit includes a reduction in current state and local tax expense and a one time benefit of $4.2 million in reduction of deferred tax liabilities reflecting the lower tax rates.


-29-


Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

Nine months ended September 30,

2023

2022

VITAS

Impact of deferred rate tax change

$

1,772 

$

-

Direct costs related to COVID-19

-

(231)

Medicare cap sequestration adjustment

-

(103)

Roto-Rooter

Amortization of reacquired franchise agreements

(5,412)

(5,186)

Impact of deferred rate tax change

3,559 

-

Litigation settlements

(1,577)

-

Direct costs related to COVID-19

-

(727)

Corporate

Stock option expense

(18,884)

(16,220)

Long-term incentive compensation

(6,989)

(4,343)

Impact of deferred rate tax change

(1,090)

-

Excess tax benefits on stock compensation

3,376 

4,390 

Direct costs related to COVID-19

-

(68)

Total

$

(25,245)

$

(22,488)

Nine months ended September 30, 2023 versus 2022 - Segment Results

Net income/(loss) for the first nine months of 2023 versus the first nine months of 2022 by segment (in thousands):

Nine months ended September 30,

2023

2022

VITAS

$

95,223 

$

97,779 

Roto-Rooter

142,354 

138,595 

Corporate

(55,121)

(48,876)

$

182,456 

$

187,498 

After-tax earnings as a percent of revenue at VITAS in the first nine months of 2023 was 9.9% as compared to 10.9% in the first nine months of 2022. VITAS’ after-tax earnings decreased primarily due to the $18.0 million in after-tax expense related to VITAS’ licensed healthcare worker retention bonus program recorded in 2023 compared to the $7.1 million recorded for the program in 2022.

Roto-Rooter’s after-tax earnings as a percent of revenue for the first nine months of 2023 was 20.0%, as compared to 19.9% in the first nine months of 2022.

After-tax Corporate expenses for the first nine months of 2023 increased 12.8% when compared to the first nine months of 2022 due to an $5.3 million increase in stock-based compensation.


-30-


CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2023

(in thousands)(unaudited)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

2023 (a)

                         

                         

                         

                         

Service revenues and sales

$

333,728 

$

230,804 

$

-

$

564,532 

Cost of services provided and goods sold

253,731 

108,627 

-

362,358 

Selling, general and administrative expenses

25,256 

55,141 

19,205 

99,602 

Depreciation

5,009 

7,836 

13 

12,858 

Amortization

26 

2,495 

-

2,521 

Other operating (income)/expense

(53)

396 

-

343 

Total costs and expenses

283,969 

174,495 

19,218 

477,682 

Income/(loss) from operations

49,759 

56,309 

(19,218)

86,850 

Interest expense

(52)

(131)

(261)

(444)

Intercompany interest income/(expense)

4,935 

3,040 

(7,975)

-

Other income—net

849 

34 

5,976 

6,859 

Income/(expense) before income taxes

55,491 

59,252 

(21,478)

93,265 

Income taxes

(11,160)

(8,925)

1,778 

(18,307)

Net income/(loss)

$

44,331 

$

50,327 

$

(19,700)

$

74,958 

(a) The following amounts are included in net income (in thousands):

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

Pretax benefit/(cost):

Stock option expense

$

-

$

-

$

(5,495)

$

(5,495)

Long-term incentive compensation

-

-

(3,553)

(3,553)

Amortization of reacquired franchise agreements

-

(2,352)

-

(2,352)

Litigation settlements

-

(300)

-

(300)

Total

$

-

$

(2,652)

$

(9,048)

$

(11,700)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

After-tax benefit/(cost):

Stock option expense

$

-

$

-

$

(4,924)

$

(4,924)

Impact of deferred rate tax change

1,772 

3,559 

(1,090)

4,241 

Long-term incentive compensation

-

-

(3,210)

(3,210)

Amortization of reacquired franchise agreements

-

(1,954)

-

(1,954)

Litigation settlements

-

(286)

-

(286)

Excess tax benefits on stock compensation

-

-

225 

225 

Total

$

1,772 

$

1,319 

$

(8,999)

$

(5,908)


-31-


CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2022

(in thousands)(unaudited)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

2022 (a)

                         

                         

                         

                         

Service revenues and sales

$

296,536 

$

229,936 

$

-

$

526,472 

Cost of services provided and goods sold

239,755 

107,179 

-

346,934 

Selling, general and administrative expenses

21,581 

53,225 

9,186 

83,992 

Depreciation

5,281 

6,855 

18 

12,154 

Amortization

26 

2,494 

-

2,520 

Other operating expense/(income)

26 

(11)

-

15 

Total costs and expenses

266,669 

169,742 

9,204 

445,615 

Income/(loss) from operations

29,867 

60,194 

(9,204)

80,857 

Interest expense

(44)

(91)

(1,136)

(1,271)

Intercompany interest income/(expense)

4,842 

2,371 

(7,213)

-

Other (expense)/income—net

26 

36 

(3,177)

(3,115)

Income/(expense) before income taxes

34,691 

62,510 

(20,730)

76,471 

Income taxes

(8,605)

(14,924)

3,931 

(19,598)

Net income/(loss)

$

26,086 

$

47,586 

$

(16,799)

$

56,873 

(a) The following amounts are included in net income (in thousands):

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

Pretax benefit/(cost):

Stock option expense

$

-

$

-

$

(4,676)

$

(4,676)

Amortization of reacquired franchise agreements

-

(2,352)

-

(2,352)

Long-term incentive compensation

-

-

(2,050)

(2,050)

Direct costs related to COVID-19

-

-

(89)

(89)

Total

$

-

$

(2,352)

$

(6,815)

$

(9,167)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

After-tax benefit/(cost):

Stock option expense

$

-

$

-

$

(4,060)

$

(4,060)

Long-term incentive compensation

-

-

(1,836)

(1,836)

Amortization of reacquired franchise agreements

-

(1,729)

-

(1,729)

Direct costs related to COVID-19

-

-

(68)

(68)

Excess tax benefits on stock compensation

-

-

450 

450 

Total

$

-

$

(1,729)

$

(5,514)

$

(7,243)


-32-


CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(in thousands)(unaudited)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

2023 (a)

                         

                         

                         

                         

Service revenues and sales

$

965,066 

$

713,439 

$

-

$

1,678,505 

Cost of services provided and goods sold

770,470 

336,786 

-

1,107,256 

Selling, general and administrative expenses

71,248 

171,966 

51,470 

294,684 

Depreciation

14,907 

22,830 

41 

37,778 

Amortization

78 

7,470 

-

7,548 

Other operating (income)/expense

(15)

2,079 

-

2,064 

Total costs and expenses

856,688 

541,131 

51,511 

1,449,330 

Income/(loss) from operations

108,378 

172,308 

(51,511)

229,175 

Interest expense

(154)

(387)

(2,225)

(2,766)

Intercompany interest income/(expense)

14,393 

8,652 

(23,045)

-

Other income—net

1,109 

96 

7,160 

8,365 

Income/(expense) before income taxes

123,726 

180,669 

(69,621)

234,774 

Income taxes

(28,503)

(38,315)

14,500 

(52,318)

Net income/(loss)

$

95,223 

$

142,354 

$

(55,121)

$

182,456 

(a) The following amounts are included in net income (in thousands):

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

Pretax benefit/(cost):

Stock option expense

$

-

$

-

$

(22,376)

$

(22,376)

Long-term incentive compensation

-

-

(7,817)

(7,817)

Amortization of reacquired franchise agreements

-

(7,056)

-

(7,056)

Litigation settlements

-

(2,056)

-

(2,056)

Total

$

-

$

(9,112)

$

(30,193)

$

(39,305)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

After-tax benefit/(cost):

Stock option expense

$

-

$

-

$

(18,884)

$

(18,884)

Long-term incentive compensation

-

-

(6,989)

(6,989)

Amortization of reacquired franchise agreements

-

(5,412)

-

(5,412)

Impact of deferred rate tax change

1,772 

3,559 

(1,090)

4,241 

Litigation settlements

-

(1,577)

-

(1,577)

Excess tax benefits on stock compensation

-

-

3,376 

3,376 

Total

$

1,772 

$

(3,430)

$

(23,587)

$

(25,245)


-33-


CONSOLIDATING STATEMENTS OF INCOME

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022

(in thousands)(unaudited)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

2022 (a)

                         

                         

                         

                         

Service revenues and sales

$

893,506 

$

694,803 

$

-

$

1,588,309 

Cost of services provided and goods sold

694,528 

325,779 

-

1,020,307 

Selling, general and administrative expenses

67,181 

165,162 

29,456 

261,799 

Depreciation

16,894 

20,058 

54 

37,006 

Amortization

76 

7,482 

-

7,558 

Other operating (income)/expense

(929)

399 

-

(530)

Total costs and expenses

777,750 

518,880 

29,510 

1,326,140 

Income/(loss) from operations

115,756 

175,923 

(29,510)

262,169 

Interest expense

(142)

(319)

(2,522)

(2,983)

Intercompany interest income/(expense)

14,181 

6,751 

(20,932)

-

Other income/(expense)—net

183 

107 

(12,197)

(11,907)

Income/(expense) before income taxes

129,978 

182,462 

(65,161)

247,279 

Income taxes

(32,199)

(43,867)

16,285 

(59,781)

Net income/(loss)

$

97,779 

$

138,595 

$

(48,876)

$

187,498 

(a) The following amounts are included in net income (in thousands):

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

Pretax benefit/(cost):

Stock option expense

$

-

$

-

$

(19,343)

$

(19,343)

Amortization of reacquired franchise agreements

-

(7,056)

-

(7,056)

Long-term incentive compensation

-

-

(4,877)

(4,877)

Direct costs related to COVID-19

(310)

(988)

(89)

(1,387)

Medicare cap sequestration adjustment

(138)

-

-

(138)

Total

$

(448)

$

(8,044)

$

(24,309)

$

(32,801)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

After-tax benefit/(cost):

Stock option expense

$

-

$

-

$

(16,220)

$

(16,220)

Amortization of reacquired franchise agreements

-

(5,186)

-

(5,186)

Long-term incentive compensation

-

-

(4,343)

(4,343)

Direct costs related to COVID-19

(231)

(727)

(68)

(1,026)

Medicare cap sequestration adjustment

(103)

-

-

(103)

Excess tax benefits on stock compensation

-

-

4,390 

4,390 

Total

$

(334)

$

(5,913)

$

(16,241)

$

(22,488)


-34-


Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

Chemed Corporation and Subsidiary Companies

(in thousands)

Chemed

For the three months ended September 30, 2023

VITAS

Roto-Rooter

Corporate

Consolidated

                         

                         

                         

Net income/(loss)

$

44,331 

$

50,327 

$

(19,700)

$

74,958 

Add/(deduct):

Interest expense

52 

131 

261 

444 

Income taxes

11,160 

8,925 

(1,778)

18,307 

Depreciation

5,009 

7,836 

13 

12,858 

Amortization

26 

2,495 

-

2,521 

EBITDA

60,578 

69,714 

(21,204)

109,088 

Add/(deduct):

Intercompany interest expense/(income)

(4,935)

(3,040)

7,975 

-

Interest income

(847)

(34)

(1,719)

(2,600)

Stock option expense

-

-

5,495 

5,495 

Long-term incentive compensation

-

-

3,553 

3,553 

Litigation settlements

-

300 

-

300 

Adjusted EBITDA

$

54,796 

$

66,940 

$

(5,900)

$

115,836 

Chemed

For the three months ended September 30, 2022

VITAS

Roto-Rooter

Corporate

Consolidated

Net income/(loss)

$

26,086 

$

47,586 

$

(16,799)

$

56,873 

Add/(deduct):

Interest expense

44 

91 

1,136 

1,271 

Income taxes

8,605 

14,924 

(3,931)

19,598 

Depreciation

5,281 

6,855 

18 

12,154 

Amortization

26 

2,494 

-

2,520 

EBITDA

40,042 

71,950 

(19,576)

92,416 

Add/(deduct):

Intercompany interest expense/(income)

(4,842)

(2,371)

7,213 

-

Interest income

(27)

(35)

-

(62)

Stock option expense

-

-

4,676 

4,676 

Long-term incentive compensation

-

-

2,050 

2,050 

Direct costs related to COVID-19

-

-

89 

89 

Adjusted EBITDA

$

35,173 

$

69,544 

$

(5,548)

$

99,169 


-35-


Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

Chemed Corporation and Subsidiary Companies

(in thousands)

Chemed

For the nine months ended September 30, 2023

VITAS

Roto-Rooter

Corporate

Consolidated

                         

                         

                         

Net income/(loss)

$

95,223 

$

142,354 

$

(55,121)

$

182,456 

Add/(deduct):

Interest expense

154 

387 

2,225 

2,766 

Income taxes

28,503 

38,315 

(14,500)

52,318 

Depreciation

14,907 

22,830 

41 

37,778 

Amortization

78 

7,470 

-

7,548 

EBITDA

138,865 

211,356 

(67,355)

282,866 

Add/(deduct):

Intercompany interest expense/(income)

(14,393)

(8,652)

23,045 

-

Interest income

(1,046)

(96)

(1,720)

(2,862)

Stock option expense

-

-

22,376 

22,376 

Long-term incentive compensation

-

-

7,817 

7,817 

Litigation settlements

-

2,056 

-

2,056 

Adjusted EBITDA

$

123,426 

$

204,664 

$

(15,837)

$

312,253 

Chemed

For the nine months ended September 30, 2022

VITAS

Roto-Rooter

Corporate

Consolidated

Net income/(loss)

$

97,779 

$

138,595 

$

(48,876)

$

187,498 

Add/(deduct):

Interest expense

142 

319 

2,522 

2,983 

Income taxes

32,199 

43,867 

(16,285)

59,781 

Depreciation

16,894 

20,058 

54 

37,006 

Amortization

76 

7,482 

-

7,558 

EBITDA

147,090 

210,321 

(62,585)

294,826 

Add/(deduct):

Intercompany interest expense/(income)

(14,181)

(6,751)

20,932 

-

Interest income

(181)

(107)

-

(288)

Stock option expense

-

-

19,343 

19,343 

Long-term incentive compensation

-

-

4,877 

4,877 

Direct costs related to COVID-19

310 

988 

89 

1,387 

Medicare cap sequestration adjustment

138 

-

-

138 

Adjusted EBITDA

$

133,176 

$

204,451 

$

(17,344)

$

320,283 


-36-


RECONCILIATION OF ADJUSTED NET INCOME

(in thousands, except per share data)(unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2023

2022

2023

2022

Net income as reported

$

74,958 

$

56,873 

$

182,456 

$

187,498 

Add/(deduct) pre-tax cost of:

Stock option expense

5,495 

4,676 

22,376 

19,343 

Long-term incentive compensation

3,553 

2,050 

7,817 

4,877 

Amortization of reacquired franchise agreements

2,352 

2,352 

7,056 

7,056 

Litigation settlements

300 

-

2,056 

-

Direct costs related to COVID-19

-

89 

-

1,387 

Medicare cap sequestration adjustment

-

-

-

138 

Add/(deduct) tax impacts:

Tax impact of the above pre-tax adjustments (1)

(1,326)

(1,474)

(6,443)

(5,923)

Tax impact of deferred tax rate change

(4,241)

-

(4,241)

-

Excess tax benefits on stock compensation

(225)

(450)

(3,376)

(4,390)

Adjusted net income

$

80,866 

$

64,116 

$

207,701 

$

209,986 

Diluted Earnings Per Share As Reported

Net income

$

4.93 

$

3.78 

$

12.02 

$

12.41 

Average number of shares outstanding

15,200 

15,042 

15,178 

15,114 

Adjusted Diluted Earnings Per Share

Adjusted net income

$

5.32 

$

4.26 

$

13.68 

$

13.89 

Adjusted average number of shares outstanding

15,200 

15,042 

15,178 

15,114 

(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.


-37-


CHEMED CORPORATION AND SUBSIDIARY COMPANIES

OPERATING STATISTICS FOR VITAS SEGMENT

(unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

OPERATING STATISTICS

2023

2022

2023

2022

Net revenue ($000)

Homecare

$

287,389

$

256,253

$

832,554

$

771,520

Inpatient

27,818

24,526

84,312

75,714

Continuous care

22,032

18,600

63,054

57,717

Other

3,562

3,240

9,738

9,461

Subtotal

$

340,801

$

302,619

$

989,658

$

914,412

Room and board, net

(2,646)

(2,513)

(8,317)

(6,796)

Contractual allowances

(4,302)

(2,952)

(10,650)

(8,992)

Medicare cap allowance

(125)

(618)

(5,625)

(5,118)

Total

$

333,728

$

296,536

$

965,066

$

893,506

Net revenue as a percent of total before Medicare cap allowances

Homecare

84.3

%

84.7

%

84.1

%

84.4

%

Inpatient

8.2

8.1

8.5

8.3

Continuous care

6.5

6.1

6.4

6.3

Other

1.0

1.1

1.0

1.0

Subtotal

100.0

100.0

100.0

100.0

Room and board, net

(0.8)

(0.8)

(0.8)

(0.7)

Contractual allowances

(1.3)

(1.0)

(1.1)

(1.0)

Medicare cap allowance

-

(0.2)

(0.6)

(0.6)

Total

97.9

%

98.0

%

97.5

%

97.7

%

Days of care

Homecare

1,391,377

1,271,678

4,018,469

3,796,954

Nursing home

287,785

264,407

833,112

771,921

Respite

7,292

6,635

19,211

18,098

Subtotal routine homecare and respite

1,686,454

1,542,720

4,870,792

4,586,973

Inpatient

25,493

23,435

76,987

71,177

Continuous care

23,071

20,097

65,630

61,981

Total

1,735,018

1,586,252

5,013,409

4,720,131

Number of days in relevant time period

92

92

273

273

Average daily census (days)

Homecare

15,124

13,823

14,720

13,908

Nursing home

3,128

2,874

3,052

2,828

Respite

79

72

70

66

Subtotal routine homecare and respite

18,331

16,769

17,842

16,802

Inpatient

277

255

282

261

Continuous care

251

218

240

227

Total

18,859

17,242

18,364

17,290

Total Admissions

15,774

14,680

47,564

45,945

Total Discharges

15,328

14,603

45,837

46,139

Average length of stay (days)

103.1

106.2

100.8

104.9

Median length of stay (days)

17.0

17.0

16.0

16.0

ADC by major diagnosis

Cerebro

42.0

%

39.3

%

42.2

%

38.5

%

Neurological

14.7

22.0

15.9

22.3

Cancer

10.6

10.7

10.6

11.0

Cardio

16.4

15.4

16.1

15.6

Respiratory

7.2

7.2

7.1

7.3

Other

9.1

5.4

8.1

5.3

Total

100.0

%

100.0

%

100.0

%

100.0

%

Admissions by major diagnosis

Cerebro

26.6

25.9

%

26.3

%

24.2

%

Neurological

8.8

12.4

9.9

12.7

Cancer

26.1

26.6

26.0

26.2

Cardio

16.0

14.9

16.2

14.8

Respiratory

9.7

9.5

10.1

10.3

Other

12.8

10.7

11.5

11.8

Total

100.0

%

100.0

%

100.0

%

100.0

%

Estimated uncollectible accounts as a percent of revenues

1.3

%

1.0

%

1.1

%

1.0

%

Accounts receivable --

Days of revenue outstanding- excluding unapplied Medicare payments

36.4

33.8

n.a.

n.a.

Days of revenue outstanding- including unapplied Medicare payments

33.8

24.9

n.a.

n.a.


-38-


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Item 3.    Quantitative and Qualitative Disclosures about Market Risk

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At September 30, 2023, the Company had no variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

Item 4.    Controls and Procedures

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II.    OTHER INFORMATION

Item 1.    Legal Proceedings

For information regarding the Company’s legal proceedings, see Note 10, Legal and Regulatory Matters, under Part I, Item I of this Quarterly Report on Form 10-Q.

Item 1A.    Risk Factors

There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.


-39-


Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

Item 2(c).    Purchases of Equity Securities by Issuer and Affiliated Purchasers

The following table shows the activity related to our share repurchase program for the first nine months of 2023:

Total Number

Weighted Average

Cumulative Shares

Dollar Amount

of Shares

Price Paid Per

Repurchased Under

Remaining Under

Repurchased

Share

the Program

The Program

February 2011 Program 

January 1 through January 31, 2023

-

$

-

10,458,154 

$

87,867,735 

February 1 through February 28, 2023

-

-

10,458,154 

87,867,735 

March 1 through March 31, 2023

-

-

10,458,154 

$

87,867,735 

First Quarter Total

-

$

-

April 1 through April 30, 2023

-

$

-

10,458,154 

$

87,867,735 

May 1 through May 31, 2023

16,620 

537.12 

10,474,774 

78,940,805 

June 1 through June 30, 2023

8,380 

536.71 

10,483,154 

$

74,443,156 

Second Quarter Total

25,000 

$

536.98 

July 1 through July 31, 2023

-

$

-

10,483,154 

$

74,443,156 

August 1 through August 31, 2023

11,206 

508.01 

10,494,360 

68,750,411 

September 1 through September 30, 2023

17,251 

501.52 

10,511,611 

$

60,098,765 

Third Quarter Total

28,457 

$

504.07 

Item 3.    Defaults Upon Senior Securities

None.

Item 4.    Mine Safety Disclosures

None.

Item 5.    Other Information

None.


-40-


Item 6.    Exhibits

Exhibit No.

Description

31.1

Certification by Kevin J. McNamara pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.

31.2

Certification by David P. Williams pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.

31.3

Certification by Michael D. Witzeman pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.

32.1

Certification by Kevin J. McNamara pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification by David P. Williams pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.3

Certification by Michael D. Witzeman pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101 

The following materials from Chemed Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) The Condensed Consolidated Balance Sheet, (ii) The Condensed Consolidated Statement of Income, (iii) The Condensed Consolidated Statement of Cash Flows, (iv) The Condensed Statement of Equity, and (v) Notes to the Condensed Consolidated Financial Statements.

104

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in iXBRL and contained in Exhibit 101.


-41-


SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Chemed Corporation

(Registrant)

Dated:

October 27, 2023

By:

/s/ Kevin J. McNamara

Kevin J. McNamara

(President and Chief Executive Officer)

Dated:

October 27, 2023

By:

/s/ David P. Williams

David P. Williams

(Executive Vice President and Chief Financial Officer)

Dated:

October 27, 2023

By:

/s/ Michael D. Witzeman

Michael D. Witzeman

(Vice President and Controller)

-42-